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Abstract
Objectives We report cancer incidence, mortality, and
stage distributions among Asians and Paciﬁc Islanders
(API) residing in the U.S. and note health disparities, using
the cancer experience of the non-Hispanic white population
as the referent group. New databases added to publicly
available SEER*Stat software will enable public health
researchers to further investigate cancer patterns among
API groups.
Methods Cancer diagnoses among API groups occurring
from 1 January 1998 to 31 December 2002 were included
from 14 Surveillance, Epidemiology, and End Results
(SEER) Program state and regional population-based can-
cer registries covering 54% of the U.S. API population.
Cancer deaths were included from the seven states that
report death information for detailed API groups and which
cover over 68% of the total U.S. API population. Using
detailed racial/ethnic population data from the 2000
decennial census, we produced incidence rates centered on
the census year for Asian Indians/Pakistanis, Chinese,
Filipinos, Guamanians, Native Hawaiians, Japanese,
Kampucheans, Koreans, Laotians, Samoans, Tongans, and
Vietnamese. State vital records ofﬁces do not report API
deaths separately for Kampucheans, Laotians, Pakistanis,
and Tongans, so mortality rates were analyzed only for the
remaining API groups.
Results Overall cancer incidence rates for the API groups
tended be lower than overall rates for non-Hispanic whites,
with the exception of Native Hawaiian women (All cancers
rate = 488.5 per 100,000 vs. 448.5 for non-Hispanic white
women). Among the API groups, overall cancer incidence
and death rates were highest for Native Hawaiian and
Samoan men and women due to high rates for cancers of
the prostate, lung, and colorectum among Native Hawaiian
men; cancers of the prostate, lung, liver, and stomach
among Samoan men; and cancers of the breast and lung
among Native Hawaiian and Samoan women. Incidence
and death rates for cancers of the liver, stomach, and
nasopharynx were notably high in several of the API
groups and exceeded rates generally seen for non-Hispanic
white men and women. Incidence rates were lowest among
Asian Indian/Pakistani and Guamanian men and women
and Kampuchean women. Asian Indian and Guamanian
men and women also had the lowest cancer death rates.
Selected API groups had less favorable distributions of
stage at diagnosis for certain cancers than non-Hispanic
whites.
Conclusions Possible disparities in cancer incidence or
mortality between speciﬁc API groups in our study and
non-Hispanic whites (referent group) were identiﬁed for
several cancers. Unfavorable patterns of stage at diagnosis
for cancers of the colon and rectum, breast, cervix uteri,
and prostate suggest a need for cancer control interventions
in selected groups. The observed variation in cancer pat-
terns among API groups indicates the importance of
monitoring these groups separately, as these patterns may
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Introduction
A goal of the U.S. Department of Health and Human
Service’s Healthy People 2010 program is the elimination
of health disparities that occur by race and ethnicity [1].
Health disparities have been deﬁned as ‘‘…differences in
the incidence, prevalence, mortality, and burden of diseases
and other adverse health conditions that exist among spe-
ciﬁc population groups in the United States [2].’’ This
deﬁnition implies that a cancer health disparity exists when
one segment of a population is found to have higher cancer
rates (or some other measure of interest that indicates
adverse conditions) than another population segment, or
referent group. In this study, we report cancer incidence,
mortality, and stage distributions among Asians and Paciﬁc
Islanders (API) residing in the U.S. and note health dis-
parities, using the cancer experience of the non-Hispanic
white population as the referent group. We identify speciﬁc
API groups that may beneﬁt from cancer control inter-
ventions or from further analytic epidemiologic research to
follow up on etiologic leads.
Cancer surveillance systems, composed of high quality
population-based (state or metropolitan area) central cancer
registries, enable the monitoring of health disparities rela-
ted to cancer incidence, mortality, patient survival,
treatment, and quality of life [3]. The broad geographic
coverage of national surveillance programs, such as the
National Cancer Institute’s (NCI) Surveillance, Epidemi-
ology, and End Results (SEER) Program which currently
includes 26% of the U.S. population, facilitates the inclu-
sion of more detailed racial/ethnic groups in such analyses
by virtue of the large population base. Similarly, data from
several state vital records ofﬁces that collect and report
death information for an expanded set of racial/ethnic
groups enables the identiﬁcation of disparities in cancer
mortality [4]. The lack of comparably-detailed racial/ethnic
population estimates, however, often constrains U.S. health
surveillance systems to report cancer rates for combined
groups, such as API. This limitation obscures important
differences in the cancer experience of heterogeneous
populations [5–7]. As a result, national statistics on cancer
for Asian ethnic groups are not routinely available [8]. In
this study, we have taken advantage of population data
from the 2000 decennial census for detailed racial/ethnic
groups, to calculate incidence and mortality rates for sev-
eral speciﬁc API groups: Asian Indian/Pakistani, Chinese,
Filipino, Guamanian, Native Hawaiian, Japanese, Kam-
puchean, Korean, Laotian, Samoan, Tongan, and
Vietnamese (mortality data only are available for a subset
of these groups—see Materials and methods). The dat-
abases used in these analyses can be accessed, under a data
user agreement, from the SEER Web site [9].
Material and methods
Study data
Information on new cancer diagnoses among API groups
and non-Hispanic whites (referent group) occurring during
the 5-year period from 1 January 1998 to 31 December
2002 was obtained from U.S. state and regional population-
based cancer registries that participate in the NCI’s SEER
Program. The reporting areas included in this analysis
were: Atlanta, Detroit, Seattle/Puget Sound; and the states
of California (registries for Los Angeles County, the
Greater San Francisco Bay Area, and the rest of Califor-
nia), Connecticut, Hawaii, Iowa, Kentucky, Louisiana,
New Jersey, New Mexico, and Utah. These registries cover
54% of the U.S. API population [10]. The speciﬁc API
groups included in the incidence comparisons were Asian
Indian/Pakistani (combined, due to SEER coding rules
[11]), Chinese, Filipino, Guamanian, Native Hawaiian,
Japanese, Kampuchean, Korean, Laotian, Samoan, Tongan,
and Vietnamese. Approximately 7% of the API cancer
cases were classiﬁed as ‘‘Asian not otherwise speciﬁed’’
(NOS) or ‘‘Paciﬁc Islander NOS’’ and could not be inclu-
ded in the analysis. Only invasive cancers were analyzed,
with the exception of the urinary bladder. Bladder cancers
reported as either in situ or invasive were combined, since
information in medical records needed to distinguish
between these types of tumors is frequently either
unavailable or unreliable [12]. The primary cancer type
was coded according to the International Classiﬁcation of
Diseases for Oncology (ICD-O) edition in use at the time
of diagnosis, converted to ICD-O Third Edition, and then
categorized into cancer site groupings [13].
Cancer deaths occurring during the 1998–2002 study
period were identiﬁed from all deaths reported to state vital
records ofﬁces and consolidated by the National Vital
Statistics System of the National Center for Health Statis-
tics. The underlying cause of death was coded based on the
version of the International Classiﬁcation of Diseases
(ICD) in use at the time of death. Deaths due to malignant
neoplasm were then grouped to ensure comparability of
disease categories across the ICD versions [13]. Since
speciﬁcation of expanded API racial categories on death
certiﬁcates is currently required for seven states only
(California, Hawaii, Illinois, New Jersey, New York,
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[14], we restricted our mortality analyses to these areas and
groups (Table 1). Thus, the geographic coverage differs
between the incidence and mortality analyses. Approxi-
mately 72% of the API population covered in the mortality
analysis is also included in the incidence analysis. The
seven states in the mortality analysis include over 68% of
the total U.S. API population; representing 80% of Native
Hawaiians, 79% of Filipinos, 77% of Japanese, 74% of
Chinese and of Samoans, 65% of Koreans, 62% of Viet-
namese, 61% of Guamanians, and 60% of Asian Indians
[15]. Less than 0.1% of the API deaths were classiﬁed as
‘‘API NOS’’ and were excluded from the analysis. Deaths
among non-Hispanic whites in these states are also inclu-
ded for purposes of comparison.
Data analysis
Cancer incidence and mortality rates were calculated for
the combined 5-year study period, 1998–2002, as cases or
deaths per 100,000 persons. The rates were age-adjusted to
the 2000 U.S. standard population using 19 age groups
(\1, 1–4, 5–9,…, 80–84, 85+). Rates and 95% conﬁdence
intervals (95% CI) [16] were generated using SEER*Stat
software [http://www.seer.cancer.gov/seerstat/]. As rates
based on small counts (either the number of diagnosed
cases or deaths) tend to have poor reliability, they are not
shown in tables if the case or death count is \16 [17, 18].
Detailed population data for speciﬁc API groups are
available only from the decennial U.S. census. Therefore,
we centered our study on the 2000 census and used the
population counts, multiplied by ﬁve, as denominators for
incidence and mortality rate calculations. In the 2000
census, individuals were able to indicate multiple race/
ethnic responses on the census form [19]. These responses
can be tabulated as two population values for detailed API
groups; namely, the speciﬁc API group alone (counting
those who self-identiﬁed with only one API group) and the
speciﬁc API group alone or in combination with any other
racial/ethnic groups (counting those who self-identiﬁed
with either a single API group or with more than one racial/
ethnic group, at least one of which was the speciﬁc API
group of interest). Thus, the population counts for each of
the speciﬁc API groups are not mutually exclusive. Popu-
lation data for non-Hispanic whites consist of bridged
Table 1 Geographic areas included in cancer incidence and mortality rates for each racial/ethnic group, 1998–2002
Incidence rates Mortality rates
CA
a CT HI IA KY LA NJ NM UT Atlanta
metro
Detroit
metro
Seattle–Puget
Sound
b
CA, HI, IL, NJ, NY, TX, and
WA
Asian Indian or
Pakistani
c
XX –
d XX X XX X X X 2 X
Chinese X X X X X X X X X X X 9 X
Filipino X X X X X X X X X X X 11 X
Guamanian X –
e X–
e –
e –
e –
e –
e –
e –
d –
d 6X
Native Hawaiian X
f X
f
Japanese X X X X X X X X X X X 9 X
Kampuchean X X –
e –
e –
e –
e –
e –
d XX –
d 6–
g
Korean X X X X X X X X X X X 10 X
Laotian X X X X –
e X–
e –
e XX X 4 –
g
Samoan X –
e X–
e –
e –
e –
e –
e X–
d –
d 5X
Tongan X –
d X–
d –
d –
d –
d –
d X–
d –
d 1
e –
g
Vietnamese X X X X X X X X X X X 6 X
X—Indicates area was included in rate calculations
a Includes cancer registries for Los Angeles, San Francisco/Oakland, San Jose/Monterey, and all remaining areas in California combined
b Indicates number of counties within the 11-county Seattle–Puget Sound area for which population estimates were NOT suppressed by the
Census Bureau; and thus could be included in the incidence analyses
c Incidence rates calculated for combined group of Asian Indians & Pakistanis due to SEER program coding rules; mortality rates calculated
only for Asian Indians due to NCHS coding rules
d Area not included in rate calculation due to supression of population data by Census Bureau
e Area not included in rate calculation due to small population size (\1,000); see materials and methods and Statistical analysis
f Native Hawaiian rates calculated only for the state of Hawaii
g Mortality data not available from NCHS for these race/ethnic groups [3]
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123single-race estimates available for each year from 1998 to
2002 [20, 21].
Cancer registries and state vital records ofﬁces have also
begun collecting and reporting multiple race and ethnicity
information from medical records and death certiﬁcates.
These sources, however, generally include only a single
race or ethnicity designation ([99.95% of cancer diagnoses
in SEER registries, data not shown). Therefore, only single
race or ethnicity information was used for classifying cases
and deaths in this study [11, 22].
Due to the lack of consistency between racial/ethnic
information for the numerators (generally, single race from
medical records or state vital records ofﬁces) and popula-
tion denominators (either self-reported single race alone; or
single race alone or in combination with other races), we
calculated two rates for each cancer type, speciﬁc API
group, and gender. These may be considered as representing
a maximum rate (based on the smaller, single-race/ethnicity
alone denominator) [23] and a minimum rate (based on the
larger denominator that includes both multiple-race/eth-
nicity and single-race/ethnicity respondents) [24].
Census Bureau policy for Census 2000 data is to not
disclose race/ethnicity-speciﬁc population counts below
100 for a particular geographic area [25]. Thus, we were
unable to obtain comprehensive population denominators
for some of the SEER reporting areas. When race/ethnicity-
speciﬁc census population data were suppressed for an
entire registry, the registry was excluded from rate calcu-
lations for that particular API group. However, when the
census population data were suppressed for a subset of the
counties within the Seattle/Puget Sound metropolitan area,
we chose to calculate an incidence rate that included all
remaining counties for which the race/ethnic-speciﬁc
population data were not suppressed. This resulted in the
exclusion of selected counties in Seattle/Puget Sound from
incidence rate calculations for each of the API groups, with
the exception of Filipinos (Table 1).
In addition, when a speciﬁc API population group in a
SEER registry coverage area was less than 1,000 (based on
single race/ethnicity alone population data), the data for
that area was excluded from the cancer incidence rate
calculations for that group. The rationale for this exclusion
was that incidence rates for speciﬁc API groups in these
registries with small populations were generally low; sug-
gesting that misclassiﬁcation of API ethnic information in
medical records may be a bigger problem in these areas.
Using this population threshold limited the number of
geographic areas for Guamanians, Kampucheans, Laotians,
Samoans, and Tongans (Table 1), but excluded just 1–2%
of the total number of cancer cases in these groups. Cancer
incidence and mortality rates for Native Hawaiians are
reported only for the State of Hawaii due to the extensive
efforts at the Hawaii Tumor Registry to classify all cancer
patients with any native Hawaiian ancestry and because of
the unique cultural and environmental characteristics of
this group [26]. About 60% of the total U.S. Native
Hawaiian population resides in Hawaii.
We examined the distribution of stage of disease at
diagnosis for cancers of the colon and rectum, female
breast, cervix uteri, and prostate using the SEER historical
stage categories of localized, regional, and distant disease
[27]. Due to changing medical practices in characterizing
prostate cancers, we combined localized and regional
prostate cancer cases for the analysis by stage. The age-
adjusted distribution of stage at diagnosis for selected
cancers was calculated in the following manner. An age-
adjusted incidence rate was computed using the direct
method for each particular stage group for a speciﬁc cancer
site, it was then divided by the age-adjusted incidence rate
for all stages combined, and the resulting proportion was
converted to a percentage.
Results
To simplify the presentation of our ﬁndings, incidence, and
mortality rates appearing in the tables are limited to those
based on the single race/ethnicity denominators, with the
exception of Native Hawaiian rates. Since the Hawaii
Tumor Registry collects extensive multiple race/ethnicity
information on their cancer patients and classiﬁes a patient
with any native Hawaiian ancestry as native Hawaiian, the
most appropriate population denominator for a native
Hawaiian rate is the one that includes Hawaiian alone or in
any combination. Regardless of which denominators were
used, the relative rankings of the cancer sites remained the
same for all API groups, however, the magnitude of all the
rates were reduced when larger denominators (i.e., popu-
lation counts based on the speciﬁc API group alone or in
combination with other any other racial/ethnic group), were
used. Rates based on both single race/ethnicity and one or
more race/ethnicity denominators are included as appen-
dices. The appendices also include case counts and 95% CI
for the rates.
Incidence rates: Men
The overall cancer incidence rates were highest among
Native Hawaiian and Samoan men, due to high rates of
prostate and lung cancers (Table 2), but they do not exceed
the overall cancer rate for non-Hispanic white men
(Table 4). Lung cancer incidence in Native Hawaiian men,
however, was higher than that for non-Hispanic white men.
Asian Indian/Pakistani and Guamanian men had the lowest
overall cancer rates among the API groups, and Asian
230 Cancer Causes Control (2008) 19:227–256
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colorectal cancers. Prostate cancer was the leading cancer
in Asian Indian/Pakistani, Chinese, Filipino, Guamanian,
Native Hawaiian, Japanese, and Samoan men, while lung
cancer rates were highest in Kampuchean, Korean, Laotian,
Tongan, and Vietnamese men. Colorectal cancer was
among the top three cancers in Asian Indian/Pakistani,
Chinese, Filipino, Native Hawaiian, Japanese, Korean, and
men; whereas liver cancer was among the top three
in Kampuchean, Laotian, Samoan, and Vietnamese men.
Japanese men had the highest colorectal cancer rate (75.9
per 100,000; 95% CI: 71.9, 80.2) and this exceeded the rate
in non-Hispanic white men. Among Laotian men, inci-
dence rates for lung, liver, and stomach cancers all
exceeded the rate for prostate cancer; in fact, their prostate
cancer rate (30.9; 95% CI: 18.2, 51.9) was lowest among
the API groups in our study. Stomach cancer was among
the top ﬁve cancers in all API groups, with the exception of
Asian Indian/Pakistani and Filipino men, but ranked much
lower in non-Hispanic white men (Appendix Table 1).
Table 2 Top ﬁve age-adjusted cancer incidence rates
a and 95% CI by Asian or Paciﬁc Islander subgroup, 1998–2002: Men
Rank Asian Indian or Pakistani Chinese Filipino
Rate (95% CI) Rate (95% CI) Rate (95% CI)
All cancers 292.1 (277.3, 307.9) All cancers 348.8 (341.5, 356.2) All cancers 393.2 (385.0, 401.5)
1 Prostate 98.4 (90.0, 107.7) Prostate 84.8 (81.2, 88.5) Prostate 121.9 (117.3, 126.6)
2 Lung 30.8 (25.7, 36.8) Colorectum 54.0 (51.2, 57.0) Lung 72.5 (69.0, 76.1)
3 Colorectum 23.1 (19.3, 27.9) Lung 53.0 (50.1, 56.0) Colorectum 50.4 (47.5, 53.4)
4 Non-Hodgn 15.8 (12.5, 20.1) Liver 24.0 (22.1, 25.9) Non-Hodgn 19.4 (17.7, 21.4)
5 Bladder 15.8 (12.1, 20.5) Stomach 18.3 (16.6, 20.2) Liver 17.2 (15.5, 19.0)
Guamanian Native Hawaiian
b Japanese
All cancers 252.1 (189.8, 336.7) All cancers 531.6 (503.7, 561.1) All Cancers 422.4 (412.8, 432.3)
1 Prostate 131.5 (85.0, 202.4) Prostate 119.7 (106.1, 135.1) Prostate 115.0 (110.1, 120.1)
2 nr Lung 109.8 (97.4, 123.9) Colorectal 75.9 (71.9, 80.2)
3 nr Colorectal 65.7 (56.1, 77.1) Lung 49.8 (46.6, 53.3)
4 nr Bladder 21.2 (15.3, 29.1) Stomach 29.3 (26.9, 32.1)
5 nr Non-Hodgn 19.6 (14.8, 26.3) Bladder 22.9 (20.8, 25.4)
Kampuchean Korean Laotian
All cancers 372.0 (325.3, 425.5) All cancers 372.6 (357.4, 388.4) All Cancers 407.2 (360.7, 460.3)
1 Lung 82.6 (60.1, 112.6) Lung 61.1 (54.8, 68.2) Lung 87.3 (64.9, 117.4)
2 Liver 49.1 (36.3, 68.5) Colorectum 55.9 (50.2, 62.2) Liver 79.4 (60.7, 105.0)
3 Prostate 39.7 (25.0, 62.2) Prostate 55.7 (49.8, 62.3) Stomach 33.1 (19.1, 55.8)
4 Colorectum 30.0 (18.3, 49.5) Stomach 55.0 (44.6, 56.2) Prostate 30.9 (18.2, 51.9)
5 Stomach 23.8 (12.1, 44.3) Liver 35.9 (31.6, 40.8) Colorectum 30.2 (19.4, 48.8)
Samoan Tongan Vietnamese
All cancers 566.7 (498.8, 645.5) All cancers 428.8 (329.9, 555.9) All Cancers 374.3 (358.5, 390.9)
1 Prostate 144.1 (110.0, 190.4) Lung 107.0 (55.2, 193.0) Lung 72.3 (65.3, 80.2)
2 Lung 111.9 (84.4, 151.1) Prostate 85.0 (44.5, 157.4) Prostate 59.1 (52.8, 66.3)
3 Liver 54.5 (35.2, 86.9) nr Liver 55.5 (49.9, 62.0)
4 Stomach 53.0 (33.2, 86.1) nr Colorectum 41.2 (36.1, 47.1)
5 Colorectum 43.1 (26.6, 72.8) nr Stomach 25.6 (21.2, 30.9)
a Rates are average annual per 100,000 age-adjusted to the 2000 U.S. standard population for the following SEER areas: Atlanta, Detroit,
Seattle/Puget Sound; and the states of California (registries for Los Angeles County, the Greater San Francisco Bay Area, and the rest of
California), Connecticut, Hawaii, Iowa, Kentucky, Louisiana, New Jersey, New Mexico, and Utah
b Rates for Native Hawaiians are calculated using the one or more race/ethnicities population denominators for Hawaii only (See Materials and
methods)
Abbreviations: Lung = lung and bronchus; Liver = liver and intrahepatic bile duct; Non-Hodgn = non-Hodgkin lymphoma
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(50.0; 95% CI: 44.6, 56.2) and Samoan men (53.0; 95% CI:
33.2, 86.1). Liver cancer was also among the top ﬁve
cancers in Chinese, Filipino, Kampuchean, Korean, Lao-
tian, Samoan, and Vietnamese men. The liver cancer rate
was highest in Laotian men (79.4; 95% CI: 60.7, 105.0).
Rates for nasopharyngeal cancer were highest in Chinese
and Vietnamese men, but not among the top ﬁve cancers
for any group, and greatly exceeded the rate in non-His-
panic white men (Appendix Table 1). Nasopharyngeal
cancer may also have been high in other API groups, but
the number of cases in our study were too small to produce
reliable rates.
Incidence rates: Women
Native Hawaiian, Samoan, and Tongan women had the
highest overall cancer incidence rates, while Asian Indian/
Pakistani, Guamanian, and Kampuchean women had the
lowest rates (Table 3). The cancer rate in Native Hawaiian
women even exceeds that of non-Hispanic white women
(Table 4). Breast cancer was the leading cancer in each
female API group with the exception of Laotian women,
for whom lung cancer had the highest age-adjusted inci-
dence rate and breast cancer had the second highest rate,
though the variability associated with each of these rates
was large. Breast cancer incidence was highest among
Native Hawaiian women (175.8; 95% CI: 163.0, 189.4) and
exceeded the rate in non-Hispanic white women. Lung
cancer was among the top four cancers in every female API
group and Native Hawaiian women had the highest rate
(69.7; 95% CI: 61.2, 79.1). Colorectal cancer was one of
the top four cancers in all groups for whom there were
sufﬁcient data. Japanese women, similar to the men, had
the highest colorectal cancer rate (51.9; 95% CI: 49.1,
55.0) among the racial/ethnic groups, even exceeding the
rate in non-Hispanic white women. Cervical cancer was
among the top ﬁve cancers in Kampuchean, Laotian,
Samoan, and Vietnamese women and their rates exceeded
that for non-Hispanic white women (Appendix Table 1).
Endometrial cancer was among the top four leading can-
cers for all groups with the exception of Kampuchean,
Korean, Laotian, and Vietnamese women. Liver cancer
was the ﬁfth leading cancer in Kampuchean, Korean,
Laotian, and Vietnamese women. Stomach cancer was
among the top ﬁve cancers for Chinese, Japanese, and
Korean women, and greatly exceeded the rate in non-
Hispanic white women. As observed in men, nasopharyn-
geal cancer rates were highest in Chinese and Vietnamese
women, while small numbers of cases precluded an eval-
uation of the rates in many of the other API groups
(Appendix Table 1).
Stage distribution
Age-adjusted percentage stage distributions are shown for
cancers of the colon and rectum, female breast, cervix uteri,
and prostate in Figs. 1a–d, 1e. Laotian, Samoan, and Viet-
namese men had lower percentages of colorectal cancers
diagnosed at an early (localized) stage relative to the other
API groups and to non-Hispanic whites. The total number
of cases was fairly small, however, for Laotian (n = 30) and
Samoan (n = 31) men. Among women, Laotians again had
a lower percentage of localized stage diagnoses, but this
was also based on a small total number of colorectal cancers
(n = 24). For female breast cancer, Laotian, Samoan, and
Tongan women had a smaller percentage of cases diagnosed
at localized stage than the other groups. The total number of
breast cancer cases in each of these groups was 45, 94, and
35, respectively. Kampuchean, Laotian, and Samoan
women had smaller percentages of cervical cancers diag-
nosed at localized stage (total number of cervical
cancers = 22, 28, and 19, respectively). Comparisons of the
stage distribution of prostate cancer across the API groups
indicated that Kampuchean, Samoan, and Tongan men had
smaller percentages of local/regional cancers than the other
groups, though the total number of cases was limited
(n = 27, 77, and 16, respectively).
Mortality rates: Men
The overall cancer death rates were highest among Samoan
and Native Hawaiian men (Table 5) and, unlike the inci-
dence rates, exceeded the overall cancer death rate for non-
Hispanic white men (Table 4). Asian Indian men had the
lowest overall cancer mortality rate among the API groups,
largely due to relatively low rates for lung and colorectal
cancers. Lung and bronchus cancer had the highest age-
adjusted death rate for each Asian ethnic group. Native
Hawaiian men had the highest lung cancer rate (87.7 per
100,000; 95% CI: 76.4, 100.7), and exceeded the rate in
non-Hispanic white men (72.2 per 100,000; 95% CI: 71.8,
72.7). Prostate cancer mortality was among the top three
causes of cancer death in Asian Indian, Filipino, Native
Hawaiian, and Samoan men. Samoan men had the highest
rate (36.2 per 100,000; 95% CI: 18.9, 64.4), but it is based
on relatively few deaths and its conﬁdence interval
includes the rates seen for native Hawaiian and non-His-
panic white men. Colorectal cancer was among the top
three causes of cancer death in Chinese, Filipino, Native
Hawaiian, and Japanese men. Samoans had the highest
rate (31.6 per 100,000; 95% CI: 17.2, 56.0). Liver
cancer was in the top four causes of cancer death for all
male Asian ethnic groups, except, Native Hawaiians and
Japanese. Samoans also had the highest rate for this site
232 Cancer Causes Control (2008) 19:227–256
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Fig. 1 (a) Age-adjusted percentage distributions of stage at diagnosis
for colorectal cancer,1998–2002: Men. (b) Age-adjusted percentage
distributions of stage at diagnosis for colorectal cancer, 1998–2002:
Women. (c) Age-adjusted percentage distributions of stage at
diagnosis for breast cancer, 1998–2002: Women. (d) Age-adjusted
percentage distributions of stage at diagnosis for cervix uteri cancer,
1998–2002: Women. (e) Age-adjusted percentage distributions of
stage at diagnosis for prostate cancer, 1998–2002: Men
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123(32.9 per 100,000; 95% CI: 19.3, 56.1). Stomach cancers
were in the top four causes of cancer death for all male
Asian ethnic groups, except Asian Indians and Filipinos.
Samoans had the highest rate for this site as well (40.9 per
100,000; 95% CI: 24.1, 67.6).
Mortality rates: Women
Samoan and Native Hawaiian women had the highest
overall cancer death rates (Table 6), and even exceed the
cancer mortality rate for non-Hispanic white women
(Table 4). Asian Indian women had the lowest overall
cancer death rate. Lung cancer was the leading cause of
cancer death in each female API group, with the exception
of Asian Indian women, for whom breast cancer had the
highest age-adjusted rate (Table 6). Native Hawaiian
women had the highest lung cancer death rate of all the API
groups (47.6 per 100,000; 95% CI: 40.6, 55.6), but the
conﬁdence interval included the rate seen for non-Hispanic
white women. Breast cancer was among the top three
cancer causes of death for each female Asian ethnic group,
except Koreans, where it was in the top ﬁve. Samoan and
native Hawaiian women had the highest breast cancer
death rates among the API groups. Colorectal cancer was
among the top four cancers in every female API group,
except Guamanian and Samoan women, for whom the data
were too sparse to evaluate for this cancer. Liver cancer
was among the top four cancer causes of death in Chinese,
Korean, and Vietnamese women and their rates exceed the
liver cancer mortality rate for non-Hispanic white women
(Appendix Table 2). Stomach cancer was among the top
ﬁve cancer causes of death for Chinese, Native Hawaiian,
Japanese, Korean, and Vietnamese women and their rates
exceeded the rate in non-Hispanic white women (Appendix
Table 2). The cervical cancer death rate in Vietnamese
women, though not among the top ﬁve cancers, exceeded
the rate in non-Hispanic white women (Appendix Table 2).
Discussion
Possible disparities in cancer incidence and mortality were
identiﬁed for some of the API populations studied, using
non-Hispanic whites as the referent. Liver cancer incidence
and death rates were notably high among Chinese, Kam-
puchean, Korean, Laotian, Samoan, and Vietnamese men;
and the rates for all API groups and both sexes in our study
exceeded those for non-Hispanic white men and women.
Infection with hepatitis B and C viruses is the major cause
of liver cancer and individuals migrating from Asian,
Middle Eastern, and African countries, where the viruses
are endemic have been widely reported to be at increased
risk for this cancer [28]. Stomach cancer incidence and
death rates were higher for many of the API groups in our
study when compared to rates for non-Hispanic whites.
Asian Indian/Pakistani, and Filipinos were the exceptions,
with their rates being closer to those for non-Hispanic
whites. Studies of migrant populations suggest that expo-
sure early in life to Helicobacter pylori plays a role in
stomach cancer risk, in addition to possible dietary factors
[29]. A majority of the API cancer patients in our study
were born outside of the U.S., with the exception of Jap-
anese-Americans and Native Hawaiians (data not shown).
Birthplace information was missing from registry records,
however, for about 28% of the API in this study. Incidence
and death rates for nasopharyngeal cancer among Chinese,
Filipino, and Vietnamese groups in our study are several
times the magnitude of rates seen in other U.S. racial/ethnic
groups [30]. Rates may also be high in other U.S. API
groups, but the number of cases in our study is too small to
provide precise estimates. Chinese and several Southeast
populations—including Filipinos, Thais, and Vietnam-
ese—have previously been reported at increased risk for
this cancer [31] and rates are known to remain high among
Chinese immigrants to the U.S. and other countries [32].
Consumption of preserved foods beginning at an early age
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123is frequent among these groups and has been associated
with this cancer [31].
The low rates of lung, colorectal, and stomach cancers
we observed among Asian Indians, either living in India or
residing in other countries, have also been reported by
others [33–35]. Factors such as lower tobacco use and
components of the South Asian diet have been suggested as
playing important roles in these patterns [36–38]. Breast
cancer was a leading cancer among API women in our
study, as it is in other racial/ethnic groups [39], but the
breast cancer incidence rate in each API group, with the
exception of native Hawaiians, was lower than that for non-
Hispanic white women.
Though based on small numbers, we note that Samoan
women had a smaller percentage of breast cancers diag-
nosed at an early stage and their breast cancer deathrate was
among the highest of the API groups. Others have reported
low screening rates among Samoan women and note the
need for targeted efforts to improve doctor–patient com-
munication on prevention behavior [40, 41]. Samoan men
had lower percentages of colorectal and prostate cancers
diagnosed at an early stage and this may be reﬂected in their
Table 3 Top ﬁve age-adjusted cancer incidence rates
a and 95% CI by Asian or Paciﬁc Islander subgroup, 1998–2002: Women
Rank Asian Indian or Pakistani Chinese Filipina
Rate (95% CI) Rate (95% CI) Rate (95% CI)
All cancers 238.1 (226.7, 250.2) All cancers 270.4 (264.7, 276.2) All cancers 291.1 (285.3, 297.1)
1 Breast 82.1 (76.1, 88.8) Breast 77.6 (74.6, 80.6) Breast 100.4 (97.1, 103.8)
2 Colorectum 18.8 (15.5, 23.0) Colorectum 40.2 (38.0, 42.5) Colorectum 29.4 (27.5, 31.4)
3 Endometrium 13.5 (10.9, 16.7) Lung 29.7 (27.8, 31.7) Lung 26.0 (24.1, 27.9)
4 Lung 13.1 (10.2, 16.9) Endometrium 12.0 (10.9, 13.3) Endometrium 18.6 (17.2, 20.1)
5 Ovary 12.0 (9.7, 15.1) Stomach 11.1 (10.0, 12.4) Thyroid 17.7 (16.4, 19.2)
Guamanian Native Hawaiian
b Japanese
All cancers 175.6 (132.7, 233.8) All cancers 488.5 (466.5, 511.3) All Cancers 342.4 (334.5, 350.2)
1 Breast 45.0 (28.3, 78.1) Breast 175.8 (163.0, 189.4) Breast 126.5 (121.7, 131.5)
2 Lung 40.7 (22.4, 76.4) Lung 69.7 (61.2, 79.1) Colorectum 51.9 (49.1, 55.0)
3 nr Colorectum 44.0 (37.3, 51.6) Lung 24.7 (22.8, 26.8)
4 nr Endometrium 37.5 (31.9, 44.1) Endometrium 20.4 (18.5, 22.6)
5 nr Pancreas 18.6 (14.3, 23.9) Stomach 15.0 (13.6, 16.8)
Kampuchean Korean Laotian
All cancers 212.3 (185.9, 242.4) All cancers 254.5 (245.2, 264.1) All Cancers 297.9 (263.0, 337.1)
1 Breast 38.2 (28.3, 51.8) Breast 53.5 (49.7, 57.6) Lung 44.4 (31.2, 62.3)
2 Lung 24.6 (15.6, 37.8) Colorectum 35.9 (32.3, 39.8) Breast 36.9 (26.5, 51.5)
3 Colorectum 21.1 (13.1, 33.2) Lung 27.5 (24.3, 31.0) Colorectum 27.5 (17.1, 42.7)
4 Cervix Uteri 15.3 (9.3, 25.3) Stomach 26.3 (23.3, 29.7) Cervix Uteri 24.8 (16.0, 38.0)
5 Liver 14.1 (7.6, 24.9) Liver 14.4 (12.2, 17.0) Liver 23.1 (14.5, 36.4)
Samoan Tongan Vietnamese
All cancers 472.0 (421.5, 528.6) All cancers 504.7 (414.1, 616.6) All Cancers 270.6 (259.6, 282.2)
1 Breast 102.5 (81.7, 129.5) Breast 118.0 (78.1, 181.2) Breast 52.8 (48.6, 57.5)
2 Endometrium 66.1 (50.3, 88.2) Endometrium 91.2 (56.4, 150.1) Lung 34.4 (30.3, 39.1)
3 Lung 56.9 (39.6, 81.3) nr Colorectum 33.3 (29.3, 37.8)
4 Colorectum 38.6 (24.1, 60.5) nr Cervix Uteri 16.8 (14.3, 19.8)
5 Cervix Uteri 18.1 (10.6, 32.7) nr Liver 16.8 (14.0, 20.1)
a Rates are average annual per 100,000 age-adjusted to the 2000 U.S. standard population for the following SEER areas: Atlanta, Detroit,
Seattle/Puget Sound; and the states of California (registries for Los Angeles County, the Greater San Francisco Bay Area, and the rest of
California), Connecticut, Hawaii, Iowa, Kentucky, Louisiana, New Jersey, New Mexico, and Utah
b Rates for Native Hawaiians are calculated using the one or more race/ethnicities population denominators for Hawaii only (See Materials and
methods)
Abbreviations: Lung = lung and bronchus; Liver = liver and intrahepatic bile duct; Endometrium = corpus uterus, NOS
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123Table 4 Top ﬁve age-adjusted cancer rates and 95% CI for non-Hispanic white men and women, 1998–2002
Rank
Men Women
Rate (95% CI) Rate (95% CI)
Incidence
a
All cancers 587.0 (585.6, 588.5) All cancers 448.5 (447.3, 449.6)
1 Prostate 170.0 (169.3, 170.8) Breast 145.2 (144.5, 145.8)
2 Lung 89.2 (88.7, 89.8) Lung 59.0 (58.6, 59.4)
3 Colorectum 65.6 (65.2, 66.1) Colorectum 47.6 (47.2, 47.9)
4 Bladder 43.0 (42.6, 43.4) Endometrium 26.0 (25.7, 26.2)
5 Melanoma 29.3 (29.0, 29.6) Melanoma 19.3 (19.0, 19.5)
Mortality
b
All cancers 241.3 (240.5, 242.1) All cancers 171.7 (171.1, 172.2)
1 Lung 72.2 (71.8, 72.7) Lung 44.5 (44.2, 44.8)
2 Prostate 27.7 (27.4, 28.0) Breast 27.8 (27.5, 28.0)
3 Colorectum 24.6 (24.3, 24.8) Colorectum 17.3 (17.1, 17.5)
4 Pancreas 12.6 (12.4, 12.8) Ovary 9.8 (9.7, 9.9)
5 Non-Hodgkin 10.6 (10.5, 10.8) Pancreas 9.5 (9.4, 9.6)
a Rates are average annual per 100,000 age-adjusted to the 2000 U.S. standard population for the following SEER areas: Atlanta, Detroit,
Seattle/Puget Sound; and the states of California (registries for Los Angeles County, the Greater San Francisco Bay Area, and the rest of
California), Connecticut, Hawaii, Iowa, Kentucky, Louisiana, New Jersey, New Mexico, and Utah
b Rates are average annual per 100,000 age-adjusted to the 2000 U.S. standard population for the following States: California, Hawaii, Illinois,
New Jersey, New York, Texas, and Washington
Abbreviations: Lung = lung and bronchus; Endometrium = corpus uterus, NOS; Non-Hodgn = non-Hodgkin lymphoma
Table 5 Top ﬁve age-adjusted cancer mortality rates
a and 95% CI by Asian or Paciﬁc Islander subgroup, 1998–2002: Men
Rank Korean Samoan Vietnamese
Rate (95% CI) Rate (95% CI) Rate (95% CI)
All cancers 82.8 (75.7, 90.5) All cancers 167.8 (163.4, 172.4) All Cancers 155.6 (150.6, 160.8)
1 Lung 17.2 (14.1, 21.1) Lung 47.0 (44.78, 49.5) Lung 47.9 (45.7, 50.8)
2 Prostate 10.6 (7.8, 14.2) Liver 20.3 (18.8, 21.9) Prostate 17.8 (16.1, 19.8)
3 Pancreas 5.8 (4.1, 8.3) Colorectum 19.5 (18.0, 21.2) Colorectum 16.1 (14.6, 17.8)
4 Liver 5.3 (3.6, 7.7) Stomach 11.7 (10.5, 12.9) Liver 11.3 (10.1, 12.7)
5 Leukemia 4.8 (3.3, 7.1) Prostate 10.4 (9.2, 11.7) Non-Hodgkin 9.1 (7.9, 10.4)
Guamanian Native Hawaiian
b Japanese
All cancers 147.0 (106.5, 201.8) All cancers 263.7 (243.7, 285.4) All Cancers 173.7 (167.7, 179.9)
1 Lung 47.4 (28.4, 81.0) Lung 87.7 (76.4, 100.7) Lung 39.5 (36.7, 42.5)
2 nr Colorectum 26.9 (20.8, 34.9) Colorectum 25.8 (23.6, 28.3)
3 nr Prostate 21.9 (15.7, 30.1) Stomach 16.6 (14.8, 18.7)
4 nr Stomach 14.1 (9.9, 20.2) Prostate 15.2 (13.5, 17.3)
5 nr Liver 11.8 (7.9, 17.7) Pancreas 12.2 (10.6, 14.0)
Korean Samoan Vietnamese
All cancers 196.5 (186.2, 207.4) All cancers 293.9 (247.6, 348.6) All Cancers 159.9 (149.9, 170.7)
1 Lung 50.6 (45.3, 56.2) Lung 74.0 (53.6, 102.9) Lung 43.9 (38.7, 49.9)
2 Stomach 31.5 (27.5, 36.0) Stomach 40.9 (24.1, 67.6) Liver 33.8 (29.6, 38.8)
3 Liver 26.3 (23.0, 30.2) Prostate 36.2 (18.9, 64.4) Stomach 12.7 (9.8, 16.4)
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123higher mortality rates for these cancers. Increased efforts to
improve screening for these cancers in speciﬁc API groups
may be needed. These results are based on small numbers of
deaths among Samoans, however, and need to be conﬁrmed
in other studies. Furthermore, our ﬁndings must be inter-
preted cautiously, since the geographic coverage of the API
study populations included in the incidence and mortality
analyses are somewhat different.
Limitations of the source data must be recognized when
analyzing racial/ethnic patterns of disease. Evaluations of
the accuracy of cancer registry data on race/ethnicity,
which is extracted from patient medical records, have
shown varying levels of misclassiﬁcation [42–47]. A recent
comparison of self-reported race/ethnicity obtained from
interview studies with that from registry records was
conducted by the Greater Bay Area Cancer Registry
Table 5 continued
Rank Korean Samoan Vietnamese
Rate (95% CI) Rate (95% CI) Rate (95% CI)
4 Colorectum 17.6 (14.6, 21.3) Liver 32.9 (19.3, 56.1) Pancreas 8.9 (6.6, 11.9)
5 Pancreas 11.4 (9.1, 14.3) Colorectum 31.6 (17.2, 56.0) Colorectum 8.8 (6.6, 11.7)
a Rates are average annual per 100,000 age-adjusted to the 2000 U.S. standard population for the following States: California, Hawaii, Illinois,
New Jersey, New York, Texas, and Washington
b Rates for Native Hawaiians are calculated using the one or more race/ethnicities population denominators for Hawaii only (See Materials and
methods)
Abbreviations: Lung = lung and bronchus; Liver = liver and intrahepatic bile duct; Non-Hodgkin = non-Hodgkin lymphoma
Table 6 Top ﬁve age-adjusted cancer mortality rates
a and 95% CI by Asian or Paciﬁc Islander subgroup, 1998–2002: Women
Rank Asian Indian Chinese Filipina
Rate (95% CI) Rate (95% CI) Rate (95% CI)
All cancers 67.4 (62.2, 73.1) All cancers 107.7 (104.5, 110.9) All Cancers 96.1 (92.8, 99.5)
1 Breast 11.2 (9.4, 13.5) Lung 23.8 (22.4, 25.4) Breast 17.2 (15.9, 18.6)
2 Lung 6.4 (4.8, 8.5) Colorectum 12.8 (11.7, 13.9) Lung 17.2 (15.8, 18.7)
3 Colorectum 5.3 (3.8, 7.3) Breast 12.3 (11.3, 13.4) Colorectum 9.0 (8.0, 10.1)
4 Ovary 5.0 (3.7, 6.8) Liver 7.4 (6.5, 8.2) Pancreas 6.3 (5.4, 7.2)
5 Pancreas 3.5 (2.4, 5.2) Stomach 7.3 (6.5, 8.2) Ovary 5.6 (4.9, 6.5)
Guamanian Native Hawaiian
b Japanese
All cancers 98.5 (69.5, 138.8) All cancers 198.9 (184.4, 214.4) All Cancers 117.0 (112.9, 121.4)
1 nr Lung 47.6 (40.6, 55.6) Lung 19.7 (18.1, 21.5)
2 nr Breast 33.5 (27.9, 40.1) Colorectal 15.3 (13.8, 17.0)
3 nr Pancreas 16.8 (12.7, 21.8) Breast 15.1 (13.6, 16.9)
4 nr Colorectum 13.1 (9.5, 17.7) Pancreas 10.6 (9.4, 12.1)
5 nr Stomach 10.3 (9.5, 17.7) Stomach 10.2 (9.0, 11.6)
Korean Samoan Vietnamese
All cancers 108.2 (102.6, 114.1) All cancers 209.3 (176.5, 248.2) All Cancers 97.8 (91.2, 104.9)
1 Lung 20.7 (18.2, 23.4) Lung 42.0 (27.1, 63.7) Lung 20.2 (17.1, 23.7)
2 Stomach 14.5 (12.5, 16.8) Breast 36.2 (24.0, 54.9) Liver 10.9 (8.8, 13.6)
3 Colorectum 12.1 (10.3, 14.2) nr Breast 7.6 (6.1, 9.5)
4 Liver 11.7 (9.9, 13.7) nr Colorectum 7.4 (5.6, 9.7)
5 Breast 7.8 (6.5, 9.3) nr Stomach 7.0 (5.3, 9.2)
a Rates are average annual per 100,000 age-adjusted to the 2000 U.S. standard population for the following States: California, Hawaii, Illinois,
New Jersey, New York, Texas, and Washington
b Rates for Native Hawaiians are calculated using the one or more race/ethnicities population denominators for Hawaii only (See Materials and
methods)
Abbreviations: Lung = lung and bronchus; Liver = liver and intrahepatic bile duct; Non-Hodgkin = non-Hodgkin lymphoma
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123(comprising the San Francisco/Oakland and San Jose/
Monterey regions of California) [42]. They found that
sensitivities and positive predictive values (PV+) were high
for non-Hispanic Whites and Blacks and were moderately
high for Chinese (sensitivity = 77%, PV+ = 92%) leading
to a 16% underestimate of Chinese cases. For Japanese and
Filipinos, they reported comparable results of about 80%
for both sensitivity and PV+; while for Vietnamese they
reported low sensitivity (47%) and moderate PV+ (75%),
yielding a 37% underestimate for this group. There were
too few Koreans, South Asians (mostly Asian Indians),
Laotians, Kampucheans, and Paciﬁc Islanders to provide
reliable estimates of sensitivity or PV+ in their study. In
addition, about 7% of the diagnosed cancer cases in our
incidence analysis were classiﬁed as Asian NOS or Paciﬁc
Islander NOS, thereby depressing the rates we reported for
speciﬁc Asian or Paciﬁc Islander groups. To address this
problem, collaborative efforts are underway between the
SEER Program registries and the National Association of
Central Cancer Registries to improve how central registries
classify cancer patients into speciﬁc Asian or Paciﬁc
Islander groups by using name lists and information on
birthplace. Similar misclassiﬁcation problems have been
identiﬁed for death certiﬁcate information on race/ethnicity
and have been reported to result in an 11% underestimate
of mortality rates for the API group as a whole [48]. The
impact of nonspeciﬁc API race on the mortality rates in our
study is small, however, since less than 0.1% of deaths
were coded as ‘‘API, NOS.’’ These limitations suggest that
the API rates we have reported are generally biased
downward, in spite of the fact that we used the single race
population denominators in our rate calculations.
In conclusion, we found some evidence for cancer
health disparities between speciﬁc API populations and
non-Hispanic whites. The addition of population denomi-
nators for detailed API groups to SEER*Stat software
developed by the National Cancer Institute’s Surveillance
Research Program will enable public health researchers to
utilize SEER databases to further investigate cancer inci-
dence and mortality rates among these groups in the US
[8]. Additional studies might include analyses that incor-
porate tumor characteristics (e.g., cancer subsite, histology,
and grade) or other sociodemographic factors when
examining racial/ethnic differences in cancer patterns.
Appendix 1 Age-adjusted incidence rates
a for major cancers
b by race/ethnicity and sex, 1998–2002
Count Rate based on single race/ethnicity
alone denominator
Rate based on one or more
race/ethnicities denominator
Rate 95% CI Rate 95% CI
LL UL LL UL
Asian Indian & Pakistani/Men
All Sites 2,314 292.1 277.3 307.9 255.5 242.5 269.1
Prostate 701 98.4 90.0 107.7 86.1 78.8 94.2
Lung and bronchus 207 30.8 25.7 36.8 26.9 22.5 32.1
Colon and rectum 199 23.1 19.3 27.9 20.3 17.0 24.4
Lymphoma—Non-Hodgkin 142 15.8 12.5 20.1 13.8 11.0 17.5
Urinary bladder 98 15.8 12.1 20.5 13.8 10.6 17.8
Leukemia 138 12.2 9.5 15.9 10.7 8.3 13.9
Oral cavity (excl nasopharynx) 102 11.4 8.7 15.1 10.0 7.6 13.2
Liver and intrahepatic bile duct 60 8.7 6.2 12.3 7.6 5.4 10.7
Kidney and renal pelvis 64 8.4 6.0 11.7 7.3 5.3 10.2
Stomach 61 8.2 5.8 11.6 7.1 5.1 10.1
Pancreas 52 8.0 5.4 11.7 7.0 4.8 10.2
Brain and other nervous system 84 6.7 5.0 9.3 5.9 4.4 8.1
Myeloma 43 4.8 3.3 7.3 4.2 2.9 6.4
Larynx 23 4.5 2.5 7.7 3.9 2.2 6.6
Esophagus 27 3.6 2.1 6.2 3.2 1.9 5.4
Thyroid 40 2.7 1.8 4.7 2.4 1.6 4.1
Testis 38 2.3 1.3 4.5 2.0 1.2 3.9
Lymphoma—Hodgkin 36 2.0 1.4 3.7 1.7 1.2 3.2
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123Appendix 1 continued
Count Rate based on single race/ethnicity
alone denominator
Rate based on one or more
race/ethnicities denominator
Rate 95% CI Rate 95% CI
LL UL LL UL
Asian Indian & Pakistani/Women
All sites 2,229 238.1 226.7 250.2 208.2 198.4 218.6
Breast 864 82.1 76.1 88.8 72.3 67.0 78.1
Colon and rectum 147 18.8 15.5 23.0 16.4 13.5 19.9
Corpus and uterus, NOS 127 13.5 10.9 16.7 11.8 9.6 14.6
Lung and bronchus 90 13.1 10.2 16.9 11.3 8.9 14.5
Ovary 123 12.0 9.7 15.1 10.6 8.6 13.2
Lymphoma—Non-Hodgkin 92 9.4 7.3 12.3 8.2 6.4 10.7
Leukemia 86 9.0 6.8 12.0 7.8 5.9 10.4
Thyroid 111 8.3 6.6 10.7 7.3 5.9 9.4
Cervix Uteri 59 6.1 4.5 8.4 5.4 4.0 7.4
Brain and other nervous system 56 5.6 4.0 8.1 4.9 3.5 7.0
Esophagus 35 5.2 3.4 8.0 4.5 3.0 6.8
Oral cavity (excl nasopharynx) 41 5.0 3.3 7.6 4.3 2.9 6.5
Stomach 31 4.7 3.0 7.2 4.1 2.6 6.2
Pancreas 31 4.4 2.8 6.8 3.8 2.4 5.9
Myeloma 31 4.3 2.7 6.9 3.7 2.3 5.9
Liver and intrahepatic bile duct 31 3.9 2.6 6.2 3.4 2.2 5.4
Gallbladder 25 3.5 2.1 5.9 3.1 1.9 5.1
Urinary bladder 23 3.0 1.8 5.1 2.6 1.6 4.4
Kidney and renal pelvis 26 2.8 1.8 4.7 2.5 1.6 4.1
Lymphoma—Hodgkin 23 1.8 1.0 3.6 1.6 0.8 3.1
Chinese/Men
All sites 9,175 348.8 341.5 356.2 318.9 312.2 325.7
Prostate 2,209 84.8 81.2 88.5 78.2 74.9 81.7
Colon and rectum 1,400 54.0 51.2 57.0 49.6 46.9 52.3
Lung and bronchus 1,340 53.0 50.1 56.0 48.9 46.2 51.7
Liver and intrahepatic bile duct 666 24.0 22.1 25.9 21.7 20.1 23.5
Stomach 461 18.3 16.6 20.2 16.8 15.3 18.5
Urinary bladder 389 15.7 14.1 17.4 14.5 13.1 16.1
Lymphoma—Non-Hodgkin 401 14.8 13.4 16.4 13.5 12.1 14.9
Pancreas 243 9.8 8.5 11.1 9.0 7.9 10.3
Nasopharynx 277 8.9 7.9 10.1 7.9 7.0 8.9
Leukemia 231 8.7 7.6 10.0 7.6 6.6 8.7
Kidney and renal pelvis 192 7.2 6.2 8.4 6.6 5.7 7.7
Oral cavity (excl nasopharynx) 166 6.2 5.3 7.3 5.7 4.8 6.6
Esophagus 124 4.5 3.7 5.4 4.1 3.4 5.0
Brain and other nervous system 123 4.3 3.5 5.1 3.7 3.0 4.4
Thyroid 96 3.2 2.5 3.9 2.8 2.2 3.5
Larynx 78 3.0 2.3 3.8 2.7 2.2 3.5
Myeloma 74 2.7 2.1 3.5 2.5 2.0 3.2
Testis 57 1.7 1.3 2.2 1.4 1.1 1.9
Lymphoma—Hodgkin 40 1.3 0.9 1.8 1.1 0.8 1.6
Melanoma of the skin 35 1.2 0.8 1.7 1.1 0.8 1.6
Gallbladder 24 0.9 0.6 1.4 0.9 0.6 1.3
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Count Rate based on single race/ethnicity
alone denominator
Rate based on one or more
race/ethnicities denominator
Rate 95% CI Rate 95% CI
LL UL LL UL
Chinese/Women
All Sites 8,817 270.4 264.7 276.2 243.5 238.4 248.7
Breast 2,652 77.6 74.6 80.6 69.3 66.6 72.0
Colon and rectum 1,257 40.2 38.0 42.5 36.7 34.7 38.8
Lung and bronchus 923 29.7 27.8 31.7 27.2 25.5 29.0
Corpus and uterus, NOS 406 12.0 10.9 13.3 10.8 9.8 11.9
Stomach 344 11.1 10.0 12.4 10.2 9.1 11.3
Thyroid 358 10.0 9.0 11.2 8.8 7.9 9.7
Ovary 335 10.0 8.9 11.1 8.8 7.9 9.9
Lymphoma—Non-Hodgkin 316 10.0 8.9 11.1 9.0 8.0 10.0
Liver and intrahepatic bile duct 258 8.2 7.3 9.3 7.5 6.6 8.5
Pancreas 209 6.8 5.9 7.8 6.3 5.4 7.2
Leukemia 188 5.9 5.1 6.9 5.1 4.4 6.0
Cervix Uteri 193 5.6 4.9 6.5 5.0 4.3 5.8
Urinary bladder 133 4.4 3.7 5.3 4.1 3.4 4.8
Kidney and renal pelvis 126 4.0 3.3 4.8 3.6 3.0 4.3
Oral cavity (excl nasopharynx) 119 3.6 3.0 4.4 3.3 2.7 3.9
Nasopharynx 125 3.5 2.9 4.2 3.1 2.6 3.7
Brain and other nervous system 90 2.7 2.2 3.4 2.3 1.9 2.9
Myeloma 76 2.5 2.0 3.1 2.3 1.8 2.9
Gallbladder 41 1.3 1.0 1.8 1.2 0.9 1.7
Esophagus 32 1.0 0.7 1.5 0.9 0.6 1.3
Melanoma of the skin 32 1.0 0.7 1.4 0.9 0.6 1.2
Lymphoma—Hodgkin 22 0.7 0.4 1.0 0.6 0.4 0.9
Filipino/Men
All Sites 9,206 393.2 385.1 401.5 357.3 349.8 364.9
Prostate 2,768 121.9 117.3 126.6 111.6 107.4 115.9
Lung and bronchus 1,665 72.5 69.0 76.1 66.2 63.0 69.6
Colon and rectum 1,194 50.4 47.5 53.4 45.9 43.2 48.6
Lymphoma—Non-Hodgkin 467 19.4 17.7 21.4 17.5 15.9 19.3
Liver and intrahepatic bile duct 413 17.2 15.5 19.0 15.6 14.1 17.2
Urinary bladder 267 12.4 10.9 14.0 11.4 10.0 12.9
Leukemia 249 10.0 8.8 11.4 8.7 7.6 10.0
Stomach 216 9.4 8.1 10.8 8.6 7.4 9.8
Pancreas 206 9.2 8.0 10.6 8.4 7.3 9.7
Kidney and renal pelvis 232 9.2 8.0 10.5 8.3 7.3 9.5
Thyroid 163 6.1 5.1 7.1 5.4 4.6 6.3
Myeloma 131 5.8 4.9 6.9 5.3 4.4 6.4
Oral cavity (excl nasopharynx) 138 5.8 4.8 6.9 5.2 4.4 6.2
Nasopharynx 129 4.8 4.0 5.7 4.3 3.5 5.1
Brain and other nervous system 100 3.8 3.1 4.7 3.2 2.6 4.0
Larynx 65 2.9 2.2 3.7 2.6 2.0 3.4
Esophagus 65 2.7 2.1 3.5 2.5 1.9 3.2
Testis 56 1.8 1.3 2.4 1.5 1.1 2.0
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Count Rate based on single race/ethnicity
alone denominator
Rate based on one or more
race/ethnicities denominator
Rate 95% CI Rate 95% CI
LL UL LL UL
Lymphoma—Hodgkin 43 1.5 1.1 2.1 1.3 1.0 1.9
Melanoma of the skin 27 1.2 0.8 1.8 1.1 0.7 1.6
Gallbladder 22 1.0 0.6 1.6 0.9 0.6 1.5
Breast 18 0.9 0.5 1.4 0.8 0.5 1.3
Kaposi Sarcoma 24 0.8 0.5 1.3 0.7 0.5 1.1
Filipina/Women
All Sites 9,847 291.1 285.3 297.1 264.3 259.0 269.8
Breast 3,610 100.4 97.1 103.8 91.1 88.1 94.2
Colon and rectum 935 29.4 27.5 31.4 27.0 25.2 28.9
Lung and bronchus 802 26.0 24.1 27.9 23.9 22.3 25.8
Corpus and uterus, NOS 667 18.6 17.2 20.1 16.9 15.6 18.3
Thyroid 652 17.7 16.4 19.2 15.7 14.5 17.0
Lymphoma—Non-Hodgkin 379 12.2 11.0 13.6 11.2 10.0 12.4
Ovary 369 10.5 9.5 11.7 9.5 8.5 10.6
Cervix Uteri 361 10.0 9.0 11.2 9.0 8.1 10.1
Pancreas 233 7.7 6.7 8.9 7.1 6.2 8.2
Leukemia 183 5.8 4.9 6.7 5.0 4.2 5.8
Stomach 162 5.6 4.7 6.6 5.1 4.4 6.1
Liver and intrahepatic bile duct 150 5.1 4.3 6.0 4.7 3.9 5.6
Kidney and renal pelvis 162 4.8 4.1 5.7 4.4 3.7 5.1
Myeloma 126 4.2 3.5 5.0 3.9 3.2 4.7
Oral cavity (excl nasopharynx) 127 4.0 3.3 4.8 3.6 3.0 4.4
Brain and other nervous system 77 2.4 1.9 3.1 2.1 1.6 2.6
Urinary bladder 68 2.4 1.8 3.1 2.2 1.7 2.9
Lymphoma—Hodgkin 55 1.6 1.2 2.1 1.3 1.0 1.8
Nasopharynx 55 1.6 1.2 2.1 1.4 1.0 1.9
Gallbladder 43 1.4 1.0 2.0 1.3 0.9 1.8
Esophagus 34 1.1 0.8 1.6 1.0 0.7 1.5
Melanoma of the skin 27 0.8 0.5 1.2 0.7 0.5 1.1
Guamanian/Men
All Sites 79 252.1 189.8 336.7 197.8 148.8 264.7
Prostate 32 131.5 85.0 202.4 102.6 66.3 158.6
Guamanian/Women
All Sites 77 175.6 132.7 233.8 136.7 103.9 180.3
Breast 25 45.0 28.3 78.1 35.8 22.4 60.5
Lung and bronchus 16 40.7 22.4 76.4 33.0 18.2 60.1
Native Hawaiian (HI only)/Men
c
All Sites 1,664 – – – 531.6 503.7 561.1
Prostate 328 – – – 119.7 106.1 135.1
Lung and bronchus 329 – – – 109.8 97.4 123.9
Colon and rectum 198 – – – 65.7 56.1 77.1
Urinary bladder 55 – – – 21.2 15.3 29.1
Lymphoma—Non-Hodgkin 68 – – – 19.6 14.8 26.3
Stomach 62 – – – 18.8 14.1 25.3
Leukemia 58 – – – 16.3 11.8 22.7
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Count Rate based on single race/ethnicity
alone denominator
Rate based on one or more
race/ethnicities denominator
Rate 95% CI Rate 95% CI
LL UL LL UL
Liver and intrahepatic bile duct 54 – – – 16.3 11.8 22.6
Kidney and renal pelvis 54 _ _ _ 15.5 11.4 21.4
Pancreas 48 _ _ _ 15.1 10.8 21.4
Oral cavity (excl nasopharynx) 53 _ _ _ 13.7 10.1 19.2
Esophagus 33 _ _ _ 9.6 6.4 14.7
Myeloma 26 _ _ _ 8.6 5.3 14.0
Larynx 22 _ _ _ 6.9 4.2 11.7
Brain and other nervous system 29 _ _ _ 6.0 3.8 10.2
Testis 29 _ _ _ 5.3 3.5 9.0
Thyroid 23 _ _ _ 5.1 3.1 9.1
Native Hawaiian (HI only)/Women
c
All Sites 1,979 _ _ _ 488.5 466.5 511.3
Breast 736 _ _ _ 175.8 163.0 189.4
Lung and bronchus 258 _ _ _ 69.7 61.2 79.1
Colon and rectum 166 _ _ _ 44.0 37.3 51.6
Corpus and uterus, NOS 162 _ _ _ 37.5 31.9 44.1
Pancreas 68 _ _ _ 18.6 14.3 23.9
Stomach 51 _ _ _ 14.5 10.7 19.4
Thyroid 61 _ _ _ 12.6 9.5 16.5
Cervix Uteri 56 _ _ _ 12.3 9.2 16.4
Ovary 50 _ _ _ 12.1 8.9 16.3
Lymphoma—Non-Hodgkin 47 _ _ _ 11.7 8.5 16.0
Leukemia 45 _ _ _ 9.4 6.7 13.1
Liver and intrahepatic bile duct 27 _ _ _ 7.7 5.0 11.5
Urinary bladder 24 _ _ _ 6.8 4.3 10.4
Myeloma 24 _ _ _ 6.8 4.3 10.4
Oral cavity (excl nasopharynx) 25 _ _ _ 5.8 3.7 8.9
Kidney and renal pelvis 22 – _ _ 5.4 3.4 8.5
Brain and other nervous system 25 – _ _ 5.0 3.2 7.9
Japanese/Men
All Sites 7,765 422.4 412.8 432.3 389.4 380.7 398.3
Prostate 2,211 115.0 110.1 120.1 108.9 104.3 113.6
Colon and rectum 1,402 75.9 71.9 80.2 70.7 67.0 74.6
Lung and bronchus 952 49.8 46.6 53.3 47.0 44.0 50.1
Stomach 542 29.3 26.9 32.1 27.6 25.3 30.1
Urinary bladder 438 22.9 20.8 25.4 21.6 19.6 23.8
Lymphoma—Non-Hodgkin 323 18.3 16.3 20.6 16.4 14.7 18.4
Pancreas 231 12.5 10.9 14.4 11.8 10.3 13.5
Kidney and renal pelvis 210 11.5 10.0 13.4 10.6 9.2 12.1
Liver and intrahepatic bile duct 199 11.4 9.8 13.3 10.3 8.9 11.9
Leukemia 173 11.4 9.6 13.5 8.8 7.5 10.2
Oral cavity (excl nasopharynx) 155 8.5 7.2 10.2 7.9 6.7 9.3
Esophagus 131 7.5 6.2 9.1 6.9 5.8 8.2
Testis 63 4.6 3.5 6.0 3.3 2.6 4.3
Brain and other nervous system 59 4.3 3.2 5.8 3.0 2.3 4.0
242 Cancer Causes Control (2008) 19:227–256
123Appendix 1 continued
Count Rate based on single race/ethnicity
alone denominator
Rate based on one or more
race/ethnicities denominator
Rate 95% CI Rate 95% CI
LL UL LL UL
Thyroid 53 3.3 2.4 4.5 2.8 2.1 3.7
Larynx 57 3.1 2.4 4.2 2.9 2.2 3.8
Myeloma 52 2.8 2.1 3.8 2.6 1.9 3.4
Melanoma of the skin 35 2.1 1.5 3.2 1.8 1.3 2.6
Lymphoma—Hodgkin 17 1.5 0.8 2.5 0.9 0.5 1.5
Japanese/Women
All Sites 8,306 342.2 334.5 350.2 310.4 303.5 317.3
Breast 2,890 126.5 121.7 131.5 113.7 109.5 118.1
Colon and rectum 1,373 51.9 49.1 55.0 48.5 45.9 51.2
Lung and bronchus 691 24.7 22.8 26.8 23.4 21.6 25.3
Corpus and uterus, NOS 454 20.4 18.5 22.6 18.3 16.6 20.1
Stomach 414 15.0 13.6 16.8 14.2 12.8 15.7
Lymphoma—Non-Hodgkin 313 12.2 10.8 13.9 11.2 9.9 12.5
Pancreas 309 11.3 10.0 12.9 10.7 9.5 12.0
Ovary 242 11.1 9.6 12.8 9.7 8.5 11.1
Thyroid 156 8.2 6.9 9.8 6.8 5.7 8.0
Liver and intrahepatic bile duct 219 7.9 6.9 9.3 7.4 6.4 8.5
Leukemia 147 7.0 5.8 8.6 5.8 4.9 6.9
Cervix Uteri 118 6.2 5.1 7.6 5.2 4.3 6.3
Kidney and renal pelvis 122 4.8 4.0 6.0 4.4 3.6 5.3
Urinary bladder 130 4.7 3.9 5.8 4.4 3.7 5.3
Oral cavity (excl nasopharynx) 99 4.2 3.4 5.4 3.8 3.1 4.7
Brain and other nervous system 44 2.8 1.9 4.1 1.9 1.4 2.6
Myeloma 56 2.2 1.6 3.1 2.0 1.5 2.7
Melanoma of the skin 43 2.0 1.5 3.0 1.8 1.3 2.5
Esophagus 34 1.3 0.9 2.1 1.2 0.8 1.7
Gallbladder 23 0.9 0.6 1.6 0.8 0.5 1.3
Kampuchean/Men
All Sites 319 372.0 325.3 425.5 316.0 276.4 361.5
Lung and bronchus 56 82.6 60.1 112.6 69.3 50.6 94.7
Liver and intrahepatic bile duct 59 49.1 36.3 68.5 41.6 30.9 58.2
Prostate 27 39.7 25.0 62.2 33.6 21.3 52.8
Colon and rectum 30 30.0 18.3 49.5 25.8 15.7 42.7
Stomach 16 23.8 12.1 44.3 20.6 10.4 38.5
Lymphoma—Non-Hodgkin 23 22.1 12.8 39.2 18.6 10.8 33.1
Kampuchean/Women
All Sites 278 212.3 185.9 242.4 180.7 158.2 206.3
Breast 58 38.2 28.3 51.8 32.5 24.1 44.1
Lung and bronchus 26 24.6 15.6 37.8 21.0 13.3 32.4
Colon and rectum 25 21.1 13.1 33.2 17.9 11.2 28.3
Cervix Uteri 22 15.3 9.3 25.3 13.0 7.9 21.5
Liver and intrahepatic bile duct 16 14.1 7.6 24.9 12.0 6.5 21.3
Thyroid 20 13.4 7.8 23.2 11.4 6.6 19.7
Korean/Men
All Sites 2,832 372.6 357.4 388.4 356.2 341.6 371.3
Lung and bronchus 414 61.1 54.8 68.2 58.6 52.5 65.4
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Count Rate based on single race/ethnicity
alone denominator
Rate based on one or more
race/ethnicities denominator
Rate 95% CI Rate 95% CI
LL UL LL UL
Colon and rectum 437 55.9 50.2 62.2 53.5 48.1 59.6
Prostate 383 55.7 49.8 62.3 53.5 47.8 59.8
Stomach 384 50.0 44.6 56.2 47.9 42.7 53.8
Liver and intrahepatic bile duct 319 35.9 31.6 40.8 34.3 30.2 39.0
Urinary bladder 106 14.6 11.7 18.3 14.0 11.2 17.6
Lymphoma—Non-Hodgkin 112 14.5 11.7 18.1 13.8 11.1 17.2
Pancreas 88 12.5 9.7 16.0 12.0 9.3 15.4
Kidney and renal pelvis 70 9.4 7.1 12.4 8.9 6.7 11.7
Oral cavity (excl nasopharynx) 69 8.6 6.5 11.4 8.2 6.2 10.9
Leukemia 67 8.1 6.1 10.9 7.5 5.6 10.1
Esophagus 35 5.2 3.4 7.7 4.9 3.3 7.4
Gallbladder 22 4.3 2.5 7.0 4.1 2.4 6.7
Thyroid 39 3.7 2.6 5.6 3.5 2.4 5.3
Larynx 26 3.2 2.0 5.2 3.1 2.0 5.0
Brain and other nervous system 32 2.9 2.0 4.6 2.7 1.8 4.3
Myeloma 17 2.1 1.1 4.0 2.0 1.1 3.8
Nasopharynx 16 1.7 0.8 3.3 1.6 0.8 3.2
Korean/Women
All Sites 3,135 254.5 245.2 264.1 243.5 234.6 252.7
Breast 779 53.5 49.7 57.6 51.0 47.4 54.9
Colon and rectum 408 35.9 32.3 39.8 34.5 31.1 38.3
Lung and bronchus 300 27.5 24.3 31.0 26.5 23.5 29.9
Stomach 294 26.3 23.3 29.7 25.3 22.4 28.6
Liver and intrahepatic bile duct 164 14.4 12.2 17.0 13.9 11.8 16.4
Cervix Uteri 142 10.8 9.0 12.8 10.3 8.6 12.3
Thyroid 145 9.8 8.2 11.7 9.2 7.8 11.0
Pancreas 87 8.4 6.6 10.5 8.1 6.4 10.1
Corpus and uterus, NOS 115 8.0 6.6 9.8 7.7 6.3 9.3
Ovary 102 7.5 6.1 9.3 7.2 5.8 8.9
Lymphoma—Non-Hodgkin 82 7.4 5.8 9.3 7.1 5.6 9.0
Urinary bladder 47 4.9 3.6 6.7 4.8 3.4 6.4
Leukemia 61 4.6 3.5 6.1 4.2 3.2 5.6
Kidney and renal pelvis 49 4.2 3.1 5.7 4.0 2.9 5.4
Gallbladder 36 3.4 2.4 4.9 3.3 2.3 4.7
Oral cavity (excl nasopharynx) 35 2.8 1.9 4.0 2.6 1.8 3.8
Brain and other nervous system 30 2.4 1.6 3.5 2.1 1.4 3.2
Myeloma 20 2.0 1.2 3.2 1.9 1.2 3.1
Laotian/Men
All Sites 376 407.2 360.7 460.3 357.2 316.0 404.4
Lung and bronchus 64 87.3 64.9 117.4 76.6 56.8 103.6
Liver and intrahepatic bile duct 80 79.4 60.7 105.0 69.8 53.2 92.8
Stomach 22 33.1 19.1 55.8 29.6 16.9 50.3
Prostate 21 30.9 18.2 51.9 27.0 15.9 45.9
Colon and rectum 30 30.2 19.4 48.8 26.2 16.9 42.8
Pancreas 21 21.6 12.5 38.7 18.8 10.9 34.1
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Count Rate based on single race/ethnicity
alone denominator
Rate based on one or more
race/ethnicities denominator
Rate 95% CI Rate 95% CI
LL UL LL UL
Lymphoma—Non-Hodgkin 26 20.3 11.6 37.0 17.9 10.1 33.3
Laotian/Women
All Sites 299 297.9 263.0 337.1 260.5 229.9 294.7
Lung and bronchus 40 44.4 31.2 62.3 38.8 27.3 54.4
Breast 45 36.9 26.5 51.5 32.3 23.2 45.0
Colon and rectum 24 27.5 17.1 42.7 24.0 15.0 37.3
Cervix Uteri 28 24.8 16.0 38.0 21.7 14.0 33.3
Liver and intrahepatic bile duct 24 23.1 14.5 36.4 20.3 12.7 31.9
Samoan/Men
All Sites 356 566.7 498.8 645.5 471.2 415.1 535.6
Prostate 77 144.1 110.0 190.4 120.6 92.2 158.0
Lung and bronchus 70 111.9 84.4 151.1 94.1 71.0 126.0
Liver and intrahepatic bile duct 35 54.5 35.2 86.9 45.1 29.4 70.3
Stomach 30 53.0 33.2 86.1 44.7 28.0 71.3
Colon and rectum 31 43.1 26.6 72.8 35.8 22.0 59.3
Leukemia 19 23.0 10.9 49.7 18.8 8.6 39.8
Samoan/Women
All Sites 396 472.0 421.5 528.6 394.5 352.2 441.9
Breast 94 102.5 81.7 129.5 86.2 68.6 108.9
Corpus and uterus, NOS 67 66.1 50.3 88.2 55.2 41.8 73.7
Lung and bronchus 41 56.9 39.6 81.3 48.1 33.4 68.6
Colon and rectum 28 38.6 24.1 60.5 32.2 20.2 50.3
Cervix Uteri 19 18.1 10.6 32.7 15.1 8.8 27.3
Tongan/Men
All Sites 95 428.8 329.9 555.9 367.4 283.6 473.6
Lung and bronchus 18 107.0 55.2 193.0 87.9 46.3 156.2
Prostate 16 85.0 44.5 157.4 74.7 39.3 135.5
Tongan/Women
All Sites 139 504.7 414.1 616.6 430.5 352.8 526.5
Breast 35 118.0 78.1 181.2 100.8 66.7 154.9
Corpus and uterus, NOS 26 91.2 56.4 150.1 77.8 48.0 128.3
Vietnamese/Men
All Sites 3,020 374.3 358.5 390.9 351.7 336.9 367.2
Lung and bronchus 543 72.3 65.3 80.2 68.0 61.4 75.3
Prostate 415 59.1 52.8 66.3 55.6 49.6 62.3
Liver and intrahepatic bile duct 493 55.5 49.9 62.0 52.4 47.1 58.4
Colon and rectum 338 41.2 36.1 47.1 38.8 34.0 44.3
Stomach 178 25.6 21.2 30.9 24.0 19.9 28.9
Lymphoma—Non-Hodgkin 143 14.7 11.9 18.5 13.8 11.1 17.3
Urinary bladder 86 13.6 10.4 17.8 12.7 9.7 16.6
Pancreas 86 11.4 8.7 15.0 10.7 8.2 14.1
Leukemia 84 9.9 7.5 13.2 9.2 7.0 12.3
Oral cavity (excl nasopharynx) 69 7.7 5.6 10.7 7.2 5.3 10.0
Nasopharynx 75 6.7 5.1 9.1 6.3 4.8 8.6
Esophagus 43 6.5 4.4 9.7 6.1 4.1 9.1
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Count Rate based on single race/ethnicity
alone denominator
Rate based on one or more
race/ethnicities denominator
Rate 95% CI Rate 95% CI
LL UL LL UL
Kidney and renal pelvis 44 5.0 3.5 7.5 4.7 3.3 7.1
Brain and other nervous system 52 4.9 3.4 7.4 4.6 3.2 6.9
Larynx 29 4.3 2.6 7.0 4.0 2.5 6.6
Thyroid 48 4.0 2.8 6.2 3.8 2.7 5.8
Myeloma 23 2.7 1.6 4.7 2.5 1.5 4.5
Testis 19 1.2 0.7 2.8 1.1 0.7 2.6
Vietnamese/Women
All Sites 2,720 270.6 259.6 282.2 254.9 244.5 265.8
Breast 647 52.8 48.6 57.5 49.9 45.9 54.3
Lung and bronchus 290 34.4 30.3 39.1 32.5 28.5 36.9
Colon and rectum 302 33.3 29.3 37.8 31.4 27.6 35.6
Cervix Uteri 189 16.8 14.3 19.8 15.9 13.6 18.7
Liver and intrahepatic bile duct 146 16.8 14.0 20.1 15.8 13.2 18.9
Stomach 110 13.8 11.1 17.0 13.0 10.5 16.0
Thyroid 174 13.3 11.2 15.8 12.5 10.6 14.8
Lymphoma—Non-Hodgkin 116 12.0 9.7 14.8 11.3 9.1 13.9
Pancreas 81 10.0 7.8 12.7 9.4 7.3 12.0
Ovary 100 8.6 6.9 10.8 8.1 6.5 10.2
Corpus and uterus, NOS 95 8.2 6.5 10.4 7.8 6.2 9.8
Leukemia 70 6.6 4.9 8.7 6.1 4.6 8.1
Oral cavity (excl nasopharynx) 46 5.0 3.5 7.0 4.7 3.3 6.6
Myeloma 34 4.3 2.9 6.2 4.0 2.7 5.9
Urinary bladder 24 3.6 2.3 5.6 3.4 2.1 5.2
Brain and other nervous system 31 2.7 1.7 4.1 2.5 1.6 3.8
Nasopharynx 27 2.3 1.5 3.7 2.2 1.4 3.5
Gallbladder 19 2.2 1.3 3.7 2.1 1.2 3.5
Kidney and renal pelvis 16 1.7 0.9 3.1 1.6 0.9 2.9
Non - Hispanic White/Men
d
All Sites 649,731 587.0 585.6 588.5
Prostate 189,678 170.0 169.3 170.8
Lung and bronchus 98,625 89.2 88.7 89.8
Colon and rectum 71,656 65.6 65.2 66.1
Urinary bladder 46,682 43.0 42.6 43.4
Melanoma of the skin 32,981 29.3 29.0 29.6
Lymphoma—Non-Hodgkin 27,294 24.6 24.3 24.9
Kidney and renal pelvis 19,671 17.5 17.2 17.7
Leukemia 18,718 17.3 17.1 17.6
Oral cavity (excl nasopharynx) 18,462 16.2 16.0 16.5
Pancreas 14,220 13.0 12.8 13.2
Stomach 10,797 9.9 9.7 10.1
Brain and other nervous system 9,893 8.9 8.7 9.1
Esophagus 9,079 8.1 8.0 8.3
Larynx 8,101 7.1 7.0 7.3
Testis 7,816 7.0 6.9 7.2
Liver and intrahepatic bile duct 7,445 6.7 6.5 6.8
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Count Rate based on single race/ethnicity
alone denominator
Rate based on one or more
race/ethnicities denominator
Rate 95% CI Rate 95% CI
LL UL LL UL
Myeloma 7,264 6.6 6.4 6.8
Thyroid 4,996 4.3 4.2 4.5
Lymphoma—Hodgkin 3,833 3.5 3.4 3.6
Kaposi Sarcoma 1,247 1.1 1.1 1.2
Gallbladder 768 0.7 0.7 0.8
Nasopharynx 717 0.6 0.6 0.7
Non - Hispanic White/Women
d
All Sites 617,158 448.5 447.3 449.6
Breast 195,231 145.2 144.5 145.8
Lung and bronchus 83,387 59.0 58.6 59.4
Colon and rectum 70,298 47.6 47.2 47.9
Corpus and uterus, NOS 35,224 26.0 25.7 26.2
Melanoma of the skin 24,455 19.3 19.0 19.5
Lymphoma—Non-Hodgkin 24,177 17.2 17.0 17.5
Ovary 20,736 15.3 15.1 15.5
Thyroid 14,103 11.8 11.6 12.0
Urinary bladder 15,480 10.6 10.4 10.8
Leukemia 13,800 10.0 9.8 10.1
Pancreas 14,520 9.8 9.6 9.9
Kidney and renal pelvis 11,787 8.5 8.4 8.7
Cervix Uteri 9,930 8.1 7.9 8.3
Oral cavity (excl nasopharynx) 8,996 6.5 6.3 6.6
Brain and other nervous system 7,911 6.2 6.1 6.4
Stomach 6,430 4.3 4.2 4.4
Myeloma 5,986 4.1 4.0 4.2
Lymphoma—Hodgkin 3,348 2.9 2.8 3.0
Liver and intrahepatic bile duct 3,689 2.6 2.5 2.6
Esophagus 3,067 2.1 2.0 2.2
Larynx 2,255 1.7 1.6 1.7
Gallbladder 1,754 1.2 1.1 1.2
Nasopharynx 315 0.2 0.2 0.3
Kaposi Sarcoma 169 0.1 0.1 0.1
a Rates are average annual per 100,000 age-adjusted to the 2000 U.S. standard population for the following SEER areas: Atlanta, Detroit,
Seattle/Puget Sound, CA (Los Angeles, Greater Bay Region, remainder of State), CT, HI, IA, KY, LA, NJ, NM, UT
b Cancers are sorted in descending order of the rate within each race/ethnic and sex group
c Rates for Native Hawaiians are calculated using only the one or more race/ethnicities population denominator (See Materials and methods)
d Rates for Non-Hispanic Whites are calculated using the bridged single-race population denominator (See Materials and methods)
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123Appendix 2 Age-adjusted mortality rates
a for major cancers
b by race/ethnicity and sex, 1998–2002
Count Rate based on single race/ethnicity
alone denominator
Rate based on one or more
race/ethnicities denominator
Rate
b 95% CI Rate
b 95% CI
LL UL LL UL
Asian Indian/Male
All Sites 852 82.8 75.7 90.5 72.1 66.0 78.8
Lung and bronchus 160 17.2 14.1 21.1 15.0 12.3 18.4
Prostate 62 10.6 7.8 14.2 9.1 6.7 12.2
Pancreas 53 5.8 4.1 8.3 5.1 3.6 7.2
Liver and intrahepatic bile duct 54 5.3 3.6 7.7 4.6 3.1 6.7
Leukemia 73 4.8 3.3 7.1 4.2 2.9 6.1
Colon and rectum 48 4.1 2.6 6.3 3.6 2.3 5.4
Stomach 44 3.7 2.5 5.7 3.3 2.2 5.0
Urinary bladder 21 3.7 2.1 6.1 3.2 1.8 5.3
Lymphoma—Non-Hodgkin 40 3.7 2.4 5.7 3.2 2.1 5.0
Esophagus 33 3.5 2.2 5.7 3.1 1.9 4.9
Brain and other nervous system 55 3.3 2.3 5.1 2.9 2.0 4.4
Oral cavity (excl nasopharynx) 36 2.9 1.7 4.8 2.5 1.5 4.2
Myeloma 27 2.2 1.4 3.8 1.9 1.2 3.3
Asian Indian/Female
All Sites 821 67.4 62.2 73.1 58.7 54.2 63.6
Breast 178 11.2 9.4 13.5 9.9 8.3 11.8
Lung and bronchus 70 6.4 4.8 8.5 5.6 4.2 7.4
Colon and rectum 55 5.3 3.8 7.3 4.6 3.3 6.3
Ovary 66 5.0 3.7 6.8 4.3 3.2 5.9
Pancreas 37 3.5 2.4 5.2 3.1 2.1 4.5
Leukemia 48 3.5 2.4 5.1 3.0 2.1 4.4
Esophagus 28 2.8 1.7 4.4 2.4 1.5 3.7
Lymphoma—Non-Hodgkin 29 2.6 1.7 4.1 2.3 1.4 3.5
Liver and intrahepatic bile duct 29 2.6 1.7 4.0 2.3 1.5 3.5
Stomach 24 2.4 1.4 4.0 2.1 1.2 3.4
Brain and other nervous system 29 2.4 1.5 3.8 2.1 1.3 3.3
Cervix Uteri 28 2.2 1.4 3.6 1.9 1.2 3.1
Myeloma 25 2.1 1.3 3.4 1.8 1.1 2.9
Corpus and uterus, NOS 22 1.6 1.0 2.7 1.4 0.8 2.4
Gallbladder 20 1.5 0.9 2.6 1.3 0.8 2.3
Chinese/Male
All Sites 5,807 167.8 163.4 172.4 156.2 152.0 160.4
Lung and bronchus 1,603 47.0 44.7 49.5 43.9 41.7 46.2
Liver and intrahepatic bile duct 761 20.3 18.8 21.9 18.8 17.4 20.2
Colon and rectum 657 19.5 18.0 21.2 18.2 16.8 19.7
Stomach 404 11.7 10.5 12.9 10.9 9.8 12.1
Prostate 292 10.4 9.2 11.7 9.8 8.7 11.0
Pancreas 291 8.5 7.5 9.6 7.9 7.0 9.0
Leukemia 216 6.1 5.3 7.1 5.7 4.9 6.5
Lymphoma—Non-Hodgkin 205 6.0 5.2 6.9 5.6 4.8 6.4
Nasopharynx 192 4.5 3.9 5.2 4.1 3.5 4.7
Esophagus 134 3.8 3.1 4.5 3.5 2.9 4.2
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Count Rate based on single race/ethnicity
alone denominator
Rate based on one or more
race/ethnicities denominator
Rate
b 95% CI Rate
b 95% CI
LL UL LL UL
Urinary bladder 109 3.6 3.0 4.4 3.4 2.8 4.2
Kidney and renal pelvis 102 2.9 2.3 3.5 2.7 2.2 3.3
Brain and other nervous system 94 2.5 2.0 3.1 2.3 1.8 2.8
Oral cavity (excl nasopharynx) 65 1.8 1.4 2.4 1.7 1.3 2.2
Myeloma 58 1.7 1.3 2.2 1.6 1.2 2.1
Larynx 33 0.9 0.6 1.3 0.9 0.6 1.2
Gallbladder 24 0.7 0.5 1.1 0.7 0.4 1.0
Melanoma of the skin 21 0.6 0.3 0.9 0.5 0.3 0.8
Chinese/Female
All Sites 4,537 107.7 104.5 110.9 99.6 96.6 102.5
Lung and bronchus 984 23.8 22.4 25.4 22.1 20.8 23.6
Colon and rectum 524 12.8 11.7 13.9 11.9 10.9 12.9
Breast 564 12.3 11.3 13.4 11.3 10.4 12.3
Liver and intrahepatic bile duct 308 7.4 6.5 8.2 6.8 6.1 7.6
Stomach 305 7.3 6.5 8.2 6.8 6.1 7.6
Pancreas 273 6.7 6.0 7.6 6.3 5.6 7.1
Ovary 229 5.2 4.6 6.0 4.8 4.2 5.5
Lymphoma—Non-Hodgkin 172 4.1 3.5 4.8 3.8 3.2 4.4
Leukemia 132 3.1 2.6 3.7 2.8 2.4 3.4
Cervix Uteri 93 2.2 1.8 2.7 2.0 1.6 2.5
Corpus and uterus, NOS 89 2.1 1.6 2.5 1.9 1.5 2.3
Brain and other nervous system 81 1.8 1.4 2.3 1.6 1.3 2.0
Kidney and renal pelvis 63 1.6 1.2 2.0 1.5 1.1 1.9
Nasopharynx 65 1.4 1.1 1.8 1.3 1.0 1.7
Myeloma 49 1.2 0.9 1.6 1.2 0.9 1.5
Esophagus 45 1.1 0.8 1.5 1.0 0.7 1.4
Urinary bladder 38 1.0 0.7 1.4 0.9 0.7 1.3
Oral cavity (excl nasopharynx) 34 0.8 0.6 1.1 0.8 0.5 1.1
Gallbladder 28 0.7 0.5 1.0 0.7 0.4 1.0
Thyroid 20 0.5 0.3 0.8 0.5 0.3 0.8
Filipino/Male
All Sites 3,890 155.6 150.6 160.8 142.3 137.7 147.0
Lung and bronchus 1,200 47.9 45.1 50.8 43.8 41.3 46.5
Prostate 377 17.8 16.1 19.8 16.6 14.9 18.3
Colon and rectum 411 16.1 14.6 17.8 14.8 13.3 16.3
Liver and intrahepatic bile duct 304 11.3 10.1 12.7 10.3 9.1 11.6
Lymphoma—Non-Hodgkin 226 9.1 7.9 10.4 8.3 7.2 9.5
Pancreas 171 7.0 6.0 8.2 6.5 5.5 7.5
Leukemia 155 5.7 4.8 6.7 5.1 4.3 6.0
Stomach 123 4.9 4.1 5.9 4.5 3.7 5.4
Myeloma 77 3.2 2.5 4.0 2.9 2.3 3.7
Kidney and renal pelvis 80 3.0 2.3 3.7 2.7 2.1 3.4
Brain and other nervous system 74 2.7 2.1 3.4 2.4 1.9 3.1
Esophagus 66 2.6 2.0 3.3 2.4 1.8 3.0
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Count Rate based on single race/ethnicity
alone denominator
Rate based on one or more
race/ethnicities denominator
Rate
b 95% CI Rate
b 95% CI
LL UL LL UL
Urinary bladder 43 2.0 1.4 2.7 1.9 1.3 2.5
Oral cavity (excl nasopharynx) 46 1.8 1.3 2.5 1.7 1.2 2.3
Nasopharynx 45 1.5 1.1 2.1 1.4 1.0 1.9
Larynx 20 0.8 0.5 1.3 0.8 0.5 1.2
Thyroid 21 0.8 0.5 1.3 0.8 0.5 1.2
Gallbladder 18 0.7 0.4 1.2 0.7 0.4 1.1
Filipino/Female
All Sites 3,429 96.1 92.8 99.5 88.4 85.3 91.5
Breast 693 17.2 15.9 18.6 15.7 14.5 17.0
Lung and bronchus 592 17.2 15.8 18.7 15.9 14.6 17.3
Colon and rectum 314 9.0 8.0 10.1 8.3 7.3 9.3
Pancreas 207 6.3 5.4 7.2 5.8 5.0 6.7
Ovary 212 5.6 4.9 6.5 5.2 4.5 6.0
Lymphoma—Non-Hodgkin 143 4.4 3.7 5.3 4.1 3.4 4.9
Liver and intrahepatic bile duct 127 3.9 3.3 4.7 3.7 3.0 4.4
Stomach 101 3.2 2.6 3.9 2.9 2.4 3.6
Leukemia 112 3.1 2.5 3.8 2.8 2.3 3.4
Cervix Uteri 113 2.8 2.3 3.5 2.6 2.1 3.2
Corpus and uterus, NOS 106 2.8 2.3 3.4 2.5 2.1 3.1
Myeloma 80 2.4 1.9 3.0 2.2 1.8 2.8
Kidney and renal pelvis 52 1.4 1.1 1.9 1.3 1.0 1.8
Brain and other nervous system 50 1.4 1.0 1.9 1.2 0.9 1.7
Thyroid 41 1.2 0.8 1.6 1.1 0.8 1.5
Urinary bladder 20 0.7 0.4 1.1 0.6 0.4 1.0
Oral cavity (excl nasopharynx) 22 0.7 0.4 1.0 0.6 0.4 1.0
Gallbladder 21 0.7 0.4 1.0 0.6 0.4 1.0
Esophagus 21 0.6 0.4 1.0 0.6 0.3 0.9
Nasopharynx 17 0.5 0.3 0.8 0.4 0.2 0.7
Guamanian/Male
All Sites 60 147.0 106.5 201.8 111.8 81.6 152.4
Lung and bronchus 23 47.4 28.4 81.0 37.4 22.7 62.8
Guamanian/Female
All Sites 48 98.5 69.5 138.8 73.4 52.4 101.9
Native Hawaiian/Male
c
All Sites 790 _ _ _ 263.7 243.7 285.4
Lung and bronchus 257 _ _ _ 87.7 76.4 100.7
Colon and rectum 81 _ _ _ 26.9 20.8 34.9
Prostate 48 _ _ _ 21.9 15.7 30.1
Stomach 44 _ _ _ 14.1 9.9 20.2
Liver and intrahepatic bile duct 38 _ _ _ 11.8 7.9 17.7
Pancreas 38 _ _ _ 11.4 7.8 16.9
Leukemia 29 _ _ _ 9.0 5.6 14.3
Esophagus 27 _ _ _ 8.4 5.4 13.4
Lymphoma—Non-Hodgkin 26 _ _ _ 8.0 4.9 13.2
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Count Rate based on single race/ethnicity
alone denominator
Rate based on one or more
race/ethnicities denominator
Rate
b 95% CI Rate
b 95% CI
LL UL LL UL
Myeloma 18 _ _ _ 5.2 3.0 9.5
Brain and other nervous system 16 _ _ _ 3.9 2.1 7.8
Native Hawaiian/Female
c
All Sites 738 _ _ _ 198.9 184.4 214.4
Lung and bronchus 173 _ _ _ 47.6 40.6 55.6
Breast 132 _ _ _ 33.5 27.9 40.1
Pancreas 61 _ _ _ 16.8 12.7 21.8
Colon and rectum 48 _ _ _ 13.1 9.5 17.7
Stomach 36 _ _ _ 10.3 7.1 14.6
Ovary 30 _ _ _ 8.4 5.6 12.3
Corpus and uterus, NOS 26 _ _ _ 6.7 4.3 10.2
Lymphoma—Non-Hodgkin 24 _ _ _ 6.6 4.2 10.2
Liver and intrahepatic bile duct 22 _ _ _ 6.4 3.9 10.0
Myeloma 18 _ _ _ 5.2 3.1 8.5
Cervix Uteri 21 _ _ _ 5.2 3.2 8.3
Leukemia 18 _ _ _ 4.6 2.7 7.7
Japanese/Male
All Sites 3,327 173.7 167.7 179.9 162.7 157.1 168.4
Lung and bronchus 777 39.5 36.7 42.5 37.3 34.7 40.0
Colon and rectum 497 25.8 23.6 28.3 24.2 22.1 26.5
Stomach 315 16.6 14.8 18.7 15.6 13.9 17.5
Prostate 284 15.2 13.5 17.3 14.6 12.9 16.5
Pancreas 234 12.2 10.6 14.0 11.5 10.0 13.1
Liver and intrahepatic bile duct 170 9.1 7.8 10.8 8.5 7.2 9.9
Esophagus 142 7.8 6.6 9.3 7.2 6.1 8.5
Lymphoma—Non-Hodgkin 146 7.5 6.3 8.9 7.0 5.9 8.3
Leukemia 111 5.9 4.9 7.3 5.4 4.4 6.5
Kidney and renal pelvis 89 4.7 3.8 5.9 4.3 3.5 5.4
Urinary bladder 88 4.6 3.6 5.8 4.3 3.5 5.4
Brain and other nervous system 45 2.6 1.9 3.7 2.2 1.6 2.9
Oral cavity (excl nasopharynx) 37 1.9 1.4 2.9 1.8 1.3 2.5
Myeloma 30 1.4 1.0 2.2 1.4 0.9 2.0
Japanese/Female
All Sites 3,276 117.0 112.9 121.4 109.2 105.4 113.2
Lung and bronchus 585 19.7 18.1 21.5 18.6 17.1 20.3
Colon and rectum 421 15.3 13.8 17.0 14.4 13.0 15.9
Breast 385 15.1 13.6 16.9 13.9 12.5 15.4
Pancreas 314 10.6 9.4 12.1 10.1 9.0 11.3
Stomach 289 10.2 9.0 11.6 9.6 8.5 10.8
Liver and intrahepatic bile duct 196 6.5 5.6 7.7 6.1 5.2 7.0
Ovary 134 5.1 4.2 6.2 4.7 3.9 5.6
Lymphoma—Non-Hodgkin 143 5.0 4.2 6.1 4.7 4.0 5.6
Leukemia 104 4.0 3.2 5.1 3.6 3.0 4.4
Corpus and uterus, NOS 83 3.1 2.5 4.1 2.9 2.3 3.6
Cervix Uteri 40 1.7 1.2 2.5 1.5 1.1 2.1
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Count Rate based on single race/ethnicity
alone denominator
Rate based on one or more
race/ethnicities denominator
Rate
b 95% CI Rate
b 95% CI
LL UL LL UL
Myeloma 47 1.6 1.2 2.3 1.5 1.1 2.0
Urinary bladder 42 1.4 1.0 2.2 1.4 1.0 1.9
Kidney and renal pelvis 37 1.3 0.9 2.1 1.2 0.9 1.8
Brain and other nervous system 28 1.2 0.8 2.0 1.0 0.7 1.5
Esophagus 33 1.1 0.8 1.8 1.1 0.7 1.6
Oral cavity (excl nasopharynx) 25 0.9 0.6 1.6 0.9 0.6 1.3
Gallbladder 23 0.8 0.5 1.4 0.7 0.5 1.1
Korean/Male
All Sites 1,762 196.5 186.2 207.4 188.6 178.6 199.0
Lung and bronchus 415 50.6 45.3 56.5 48.6 43.6 54.3
Stomach 302 31.5 27.5 36.0 30.2 26.4 34.6
Liver and intrahepatic bile duct 288 26.3 23.0 30.2 25.2 22.0 28.9
Colon and rectum 151 17.6 14.6 21.3 16.9 14.0 20.5
Pancreas 105 11.4 9.1 14.3 11.0 8.8 13.8
Prostate 43 6.8 4.7 9.5 6.5 4.6 9.2
Lymphoma—Non-Hodgkin 53 6.2 4.4 8.5 5.9 4.2 8.2
Leukemia 58 5.5 4.0 7.5 5.2 3.8 7.2
Urinary bladder 30 4.1 2.6 6.2 3.9 2.5 6.0
Esophagus 34 3.7 2.4 5.7 3.6 2.3 5.5
Gallbladder 20 3.1 1.8 5.2 3.0 1.7 5.0
Kidney and renal pelvis 28 3.0 1.9 4.7 2.9 1.9 4.5
Brain and other nervous system 27 2.0 1.3 3.4 1.9 1.2 3.3
Korean/Female
All Sites 1,561 108.2 102.6 114.1 104.2 98.8 109.9
Lung and bronchus 276 20.7 18.2 23.4 20.0 17.6 22.6
Stomach 211 14.5 12.5 16.8 14.0 12.1 16.2
Colon and rectum 171 12.1 10.3 14.2 11.7 9.9 13.7
Liver and intrahepatic bile duct 169 11.7 9.9 13.7 11.3 9.6 13.2
Breast 144 7.8 6.5 9.3 7.5 6.3 8.9
Pancreas 97 7.5 6.1 9.3 7.3 5.9 9.0
Ovary 71 4.5 3.5 5.8 4.3 3.3 5.6
Cervix Uteri 53 3.1 2.3 4.2 3.0 2.2 4.0
Lymphoma—Non-Hodgkin 39 2.9 2.1 4.1 2.8 2.0 4.0
Leukemia 43 2.6 1.8 3.6 2.5 1.7 3.5
Gallbladder 27 2.2 1.4 3.3 2.1 1.4 3.2
Corpus and uterus, NOS 26 1.7 1.1 2.6 1.6 1.0 2.5
Kidney and renal pelvis 20 1.7 1.0 2.6 1.6 1.0 2.5
Brain and other nervous system 23 1.5 0.9 2.3 1.4 0.9 2.2
Myeloma 18 1.4 0.8 2.3 1.4 0.8 2.2
Samoan/Male
All Sites 193 293.9 247.6 348.6 240.0 202.5 284.1
Lung and bronchus 54 74.0 53.6 102.9 61.2 44.4 84.6
Stomach 22 40.9 24.1 67.6 33.6 19.9 55.0
Prostate 14 36.2 18.9 64.4 29.2 15.3 51.5
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Count Rate based on single race/ethnicity
alone denominator
Rate based on one or more
race/ethnicities denominator
Rate
b 95% CI Rate
b 95% CI
LL UL LL UL
Liver and intrahepatic bile duct 22 32.9 19.3 56.1 26.8 15.8 44.9
Colon and rectum 19 31.6 17.2 56.0 25.2 13.9 44.1
Samoan/Female
All Sites 172 209.3 176.5 248.2 170.7 144.0 202.1
Lung and bronchus 29 42.0 27.1 63.7 34.1 22.2 51.4
Breast 32 36.2 24.0 54.9 29.7 19.7 44.7
Vietnamese/Male
All Sites 1,398 159.9 149.9 170.7 150.6 141.1 160.7
Lung and bronchus 368 43.9 38.7 49.9 41.4 36.5 46.9
Liver and intrahepatic bile duct 335 33.8 29.6 38.8 31.9 27.9 36.6
Stomach 95 12.7 9.8 16.4 11.9 9.2 15.4
Pancreas 76 8.9 6.6 11.9 8.4 6.3 11.2
Colon and rectum 84 8.8 6.6 11.7 8.3 6.3 11.0
Leukemia 58 7.2 5.1 10.1 6.7 4.8 9.4
Prostate 30 6.7 4.3 10.0 6.2 4.0 9.4
Lymphoma—Non-Hodgkin 53 5.2 3.6 7.5 4.9 3.4 7.1
Oral cavity (excl nasopharynx) 30 3.6 2.2 5.9 3.4 2.0 5.5
Brain and other nervous system 31 2.9 1.7 4.9 2.7 1.6 4.6
Kidney and renal pelvis 18 2.6 1.3 4.8 2.4 1.3 4.5
Esophagus 19 2.6 1.4 4.7 2.4 1.3 4.4
Urinary bladder 18 2.0 1.1 3.8 1.9 1.1 3.6
Nasopharynx 22 1.7 1.0 3.3 1.6 0.9 3.1
Vietnamese/Female
All Sites 992 97.8 91.2 104.9 92.0 85.8 98.6
Lung and bronchus 181 20.2 17.1 23.7 19.0 16.1 22.3
Liver and intrahepatic bile duct 102 10.9 8.8 13.6 10.3 8.2 12.8
Breast 102 7.6 6.1 9.5 7.2 5.7 9.0
Colon and rectum 73 7.4 5.6 9.7 7.0 5.3 9.1
Stomach 72 7.0 5.3 9.2 6.6 5.0 8.7
Pancreas 62 6.2 4.7 8.3 5.9 4.4 7.8
Ovary 54 4.5 3.3 6.2 4.3 3.1 5.9
Cervix Uteri 52 4.4 3.2 6.1 4.2 3.0 5.8
Leukemia 51 4.2 3.0 5.8 3.9 2.8 5.4
Lymphoma–Non-Hodgkin 34 4.0 2.7 5.9 3.8 2.6 5.5
Myeloma 13 1.6 0.8 3.0 1.5 0.8 2.8
Brain and other nervous system 17 1.5 0.8 2.6 1.4 0.8 2.4
Corpus and uterus, NOS 17 1.4 0.8 2.6 1.4 0.8 2.4
Non - Hispanic White/Men
d
All Sites 349,031 241.3 240.5 242.1
Lung and bronchus 106,623 72.2 71.8 72.7
Prostate 37,137 27.7 27.4 28.0
Colon and rectum 35,261 24.6 24.3 24.8
Pancreas 18,399 12.6 12.4 12.8
Lymphoma—Non-Hodgkin 15,368 10.6 10.5 10.8
Leukemia 15,119 10.6 10.4 10.8
Urinary bladder 11,682 8.4 8.2 8.6
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Count Rate based on single race/ethnicity
alone denominator
Rate based on one or more
race/ethnicities denominator
Rate
b 95% CI Rate
b 95% CI
LL UL LL UL
Esophagus 11,536 7.7 7.6 7.9
Brain and other nervous system 9,477 6.3 6.2 6.4
Kidney and renal pelvis 9,135 6.2 6.1 6.3
Liver and intrahepatic bile duct 9,091 6.1 6.0 6.3
Stomach 8,395 5.8 5.7 5.9
Melanoma of the skin 6,998 4.7 4.6 4.8
Myeloma 6,454 4.5 4.4 4.6
Oral cavity a(excluding Nasopharynx) 5,605 3.7 3.6 3.8
Larynx 3,316 2.2 2.2 2.3
Lymphoma—Hodgkin 936 0.6 0.6 0.7
Gallbladder 683 0.5 0.4 0.5
Thyroid 673 0.5 0.4 0.5
Breast 504 0.3 0.3 0.4
Testis 475 0.3 0.3 0.4
Nasopharynx 383 0.3 0.2 0.3
Non - Hispanic White/Women
d
All Sites 341,117 171.7 171.1 172.2
Lung and bronchus 87,084 44.5 44.2 44.8
Breast 53,534 27.8 27.5 28.0
Colon and rectum 36,430 17.3 17.1 17.5
Ovary 18,962 9.8 9.6 9.9
Pancreas 19,471 9.5 9.4 9.6
Lymphoma—Non-Hodgkin 14,024 6.8 6.7 7.0
Leukemia 12,132 6.0 5.9 6.1
Corpus and uterus, NOS 8,368 4.2 4.1 4.3
Brain and other nervous system 7,602 4.2 4.1 4.3
Myeloma 5,948 2.9 2.8 3.0
Stomach 5,930 2.8 2.8 2.9
Kidney and renal pelvis 5,611 2.8 2.7 2.9
Liver and intrahepatic bile duct 5,546 2.7 2.7 2.8
Urinary bladder 5,228 2.4 2.3 2.5
Cervix Uteri 4,206 2.4 2.3 2.5
Melanoma of the skin 4,075 2.2 2.1 2.2
Corpus Uteri 3,822 1.9 1.9 2.0
Esophagus 3,766 1.8 1.8 1.9
Oral cavity a(excluding Nasopharynx) 3,142 1.6 1.5 1.6
Gallbladder 1,675 0.8 0.8 0.9
Larynx 992 0.5 0.5 0.6
Lymphoma—Hodgkin 800 0.5 0.4 0.5
Thyroid 917 0.5 0.4 0.5
Nasopharynx 245 0.1 0.1 0.1
a Ratesareaverageannualper100,000age-adjustedtothe2000U.S.standardpopulationforthefollowingStates:CA,HI,IL,NJ,NY,TX,andWA
b Cancers are sorted in descending order of the rate within each race/ethnic and sex group
c Rates for Native Hawaiians are calculated using only the one or more race/ethnicities population denominator (See Materials and methods)
d Rates for Non-Hispanic Whites are calculated using the bridged single-race population denominator (See Materials and methods)
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